US20030206887A1
(en)
*
|
1992-05-14 |
2003-11-06 |
David Morrissey |
RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA)
|
US20030216335A1
(en)
*
|
2001-11-30 |
2003-11-20 |
Jennifer Lockridge |
Method and reagent for the modulation of female reproductive diseases and conditions
|
US9096636B2
(en)
|
1996-06-06 |
2015-08-04 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds and their use in gene modulation
|
EP1555317B1
(en)
|
1998-03-20 |
2011-09-28 |
Commonwealth Scientific And Industrial Research Organisation |
Synthetic genes and genetic constructs comprising the same
|
AUPP249298A0
(en)
|
1998-03-20 |
1998-04-23 |
Ag-Gene Australia Limited |
Synthetic genes and genetic constructs comprising same I
|
CA2361201A1
(en)
*
|
1999-01-28 |
2000-08-03 |
Medical College Of Georgia Research Institute, Inc. |
Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
|
DE19956568A1
(de)
*
|
1999-01-30 |
2000-08-17 |
Roland Kreutzer |
Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
|
US7601494B2
(en)
|
1999-03-17 |
2009-10-13 |
The University Of North Carolina At Chapel Hill |
Method of screening candidate compounds for susceptibility to biliary excretion
|
US20070021979A1
(en)
*
|
1999-04-16 |
2007-01-25 |
Cosentino Daniel L |
Multiuser wellness parameter monitoring system
|
AU781598B2
(en)
*
|
1999-04-21 |
2005-06-02 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for inhibiting the function of polynucleotide sequences
|
US6423885B1
(en)
|
1999-08-13 |
2002-07-23 |
Commonwealth Scientific And Industrial Research Organization (Csiro) |
Methods for obtaining modified phenotypes in plant cells
|
US7531718B2
(en)
|
1999-08-26 |
2009-05-12 |
Monsanto Technology, L.L.C. |
Nucleic acid sequences and methods of use for the production of plants with modified polyunsaturated fatty acids
|
DE60037735T2
(de)
|
1999-08-26 |
2009-01-02 |
Calgene Llc, Davis |
Pflanzen mit veränderten mehrfachungesättigten fettsäuren
|
US7067722B2
(en)
|
1999-08-26 |
2006-06-27 |
Monsanto Technology Llc |
Nucleic acid sequences and methods of use for the production of plants with modified polyunsaturated fatty acids
|
GB9925459D0
(en)
|
1999-10-27 |
1999-12-29 |
Plant Bioscience Ltd |
Gene silencing
|
GB9927444D0
(en)
*
|
1999-11-19 |
2000-01-19 |
Cancer Res Campaign Tech |
Inhibiting gene expression
|
DE10100586C1
(de)
*
|
2001-01-09 |
2002-04-11 |
Ribopharma Ag |
Verfahren zur Hemmung der Expression eines Ziegens
|
DE10160151A1
(de)
*
|
2001-01-09 |
2003-06-26 |
Ribopharma Ag |
Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens
|
US7829693B2
(en)
|
1999-11-24 |
2010-11-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a target gene
|
US8273866B2
(en)
|
2002-02-20 |
2012-09-25 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SINA)
|
US20070026394A1
(en)
|
2000-02-11 |
2007-02-01 |
Lawrence Blatt |
Modulation of gene expression associated with inflammation proliferation and neurite outgrowth using nucleic acid based technologies
|
WO2003070918A2
(en)
|
2002-02-20 |
2003-08-28 |
Ribozyme Pharmaceuticals, Incorporated |
Rna interference by modified short interfering nucleic acid
|
US7491805B2
(en)
|
2001-05-18 |
2009-02-17 |
Sirna Therapeutics, Inc. |
Conjugates and compositions for cellular delivery
|
US8202979B2
(en)
|
2002-02-20 |
2012-06-19 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
|
US7833992B2
(en)
|
2001-05-18 |
2010-11-16 |
Merck Sharpe & Dohme |
Conjugates and compositions for cellular delivery
|
US8202846B2
(en)
|
2000-03-16 |
2012-06-19 |
Cold Spring Harbor Laboratory |
Methods and compositions for RNA interference
|
JP2003526367A
(ja)
|
2000-03-16 |
2003-09-09 |
ジェネティカ インコーポレイテッド |
Rna干渉の方法とrna干渉組成物
|
KR20080023768A
(ko)
|
2000-03-30 |
2008-03-14 |
화이트헤드 인스티튜트 포 바이오메디칼 리서치 |
Rna 간섭의 rna 서열 특이적인 매개체
|
ES2500923T3
(es)
*
|
2000-03-30 |
2014-10-01 |
The Whitehead Institute For Biomedical Research |
Mediadores específicos de secuencia de ARN de interferencia de ARN
|
US20030190635A1
(en)
*
|
2002-02-20 |
2003-10-09 |
Mcswiggen James A. |
RNA interference mediated treatment of Alzheimer's disease using short interfering RNA
|
WO2005003350A2
(en)
*
|
2003-06-27 |
2005-01-13 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED TREATMENT OF ALZHEIMER’S DISEASE USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US20080032942A1
(en)
|
2000-08-30 |
2008-02-07 |
Mcswiggen James |
RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA)
|
AU2001297906B2
(en)
*
|
2000-10-31 |
2007-07-19 |
Commonwealth Scientific And Industrial Research Organisation |
Method and means for producing barley yellow dwarf virus resistant cereal plants
|
US20020173478A1
(en)
*
|
2000-11-14 |
2002-11-21 |
The Trustees Of The University Of Pennsylvania |
Post-transcriptional gene silencing by RNAi in mammalian cells
|
CZ302719B6
(cs)
*
|
2000-12-01 |
2011-09-21 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Izolovaná molekula dvouretezcové RNA, zpusob její výroby a její použití
|
US8546143B2
(en)
|
2001-01-09 |
2013-10-01 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a target gene
|
DE10100587C1
(de)
*
|
2001-01-09 |
2002-11-21 |
Ribopharma Ag |
Verfahren zur Hemmung der Expression eines Zielgens
|
US7423142B2
(en)
|
2001-01-09 |
2008-09-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of anti-apoptotic genes
|
US7767802B2
(en)
|
2001-01-09 |
2010-08-03 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of anti-apoptotic genes
|
DE10100588A1
(de)
*
|
2001-01-09 |
2002-07-18 |
Ribopharma Ag |
Verfahren zur Hemmung der Expression eines Zielgens
|
WO2003035869A1
(de)
*
|
2001-10-26 |
2003-05-01 |
Ribopharma Ag |
Verwendung einer doppelsträngigen ribonukleinsäure zur gezielten hemmung der expression eines vorgegebenen zielgens
|
GB0104948D0
(en)
*
|
2001-02-28 |
2001-04-18 |
Novartis Res Foundation |
Novel methods
|
US20040019001A1
(en)
*
|
2002-02-20 |
2004-01-29 |
Mcswiggen James A. |
RNA interference mediated inhibition of protein typrosine phosphatase-1B (PTP-1B) gene expression using short interfering RNA
|
AU2002316135B9
(en)
|
2001-05-18 |
2009-05-28 |
Sirna Therapeutics, Inc. |
Conjugates and compositions for cellular delivery
|
US20040198682A1
(en)
*
|
2001-11-30 |
2004-10-07 |
Mcswiggen James |
RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (siNA)
|
US20050124566A1
(en)
*
|
2001-05-18 |
2005-06-09 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of myostatin gene expression using short interfering nucleic acid (siNA)
|
US20050203040A1
(en)
*
|
2001-05-18 |
2005-09-15 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of vascular cell adhesion molecule (VCAM) gene expression using short interfering nucleic acid (siNA)
|
US20030175950A1
(en)
*
|
2001-05-29 |
2003-09-18 |
Mcswiggen James A. |
RNA interference mediated inhibition of HIV gene expression using short interfering RNA
|
WO2004097020A2
(en)
*
|
2003-04-25 |
2004-11-11 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of map kinase gene expression
|
US20050196767A1
(en)
*
|
2001-05-18 |
2005-09-08 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of GRB2 associated binding protein (GAB2) gene expression using short interfering nucleic acis (siNA)
|
US7109165B2
(en)
|
2001-05-18 |
2006-09-19 |
Sirna Therapeutics, Inc. |
Conjugates and compositions for cellular delivery
|
US20050233997A1
(en)
*
|
2001-05-18 |
2005-10-20 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of matrix metalloproteinase 13 (MMP13) gene expression using short interfering nucleic acid (siNA)
|
US20050014172A1
(en)
|
2002-02-20 |
2005-01-20 |
Ivan Richards |
RNA interference mediated inhibition of muscarinic cholinergic receptor gene expression using short interfering nucleic acid (siNA)
|
US20050159381A1
(en)
*
|
2001-05-18 |
2005-07-21 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of chromosome translocation gene expression using short interfering nucleic acid (siNA)
|
US20050176025A1
(en)
*
|
2001-05-18 |
2005-08-11 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of B-cell CLL/Lymphoma-2 (BCL-2) gene expression using short interfering nucleic acid (siNA)
|
AU2004266311B2
(en)
*
|
2001-05-18 |
2009-07-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
US20050143333A1
(en)
*
|
2001-05-18 |
2005-06-30 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA)
|
US20050148530A1
(en)
|
2002-02-20 |
2005-07-07 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US20050159382A1
(en)
*
|
2001-05-18 |
2005-07-21 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of polycomb group protein EZH2 gene expression using short interfering nucleic acid (siNA)
|
US20050159378A1
(en)
|
2001-05-18 |
2005-07-21 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA)
|
US9994853B2
(en)
|
2001-05-18 |
2018-06-12 |
Sirna Therapeutics, Inc. |
Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
|
US20050196765A1
(en)
*
|
2001-05-18 |
2005-09-08 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of checkpoint Kinase-1 (CHK-1) gene expression using short interfering nucleic acid (siNA)
|
WO2005014811A2
(en)
*
|
2003-08-08 |
2005-02-17 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF XIAP GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US20050158735A1
(en)
*
|
2001-05-18 |
2005-07-21 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of proliferating cell nuclear antigen (PCNA) gene expression using short interfering nucleic acid (siNA)
|
WO2003070884A2
(en)
*
|
2002-02-20 |
2003-08-28 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF MDR P-GLYCOPROTEIN GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
WO2003070888A2
(en)
*
|
2002-02-20 |
2003-08-28 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of checkpoint kinase-1 (chk-1) gene expression using short interfering nucleic acid
|
US20050256068A1
(en)
|
2001-05-18 |
2005-11-17 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of stearoyl-CoA desaturase (SCD) gene expression using short interfering nucleic acid (siNA)
|
US20050182007A1
(en)
*
|
2001-05-18 |
2005-08-18 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA)
|
US20050288242A1
(en)
*
|
2001-05-18 |
2005-12-29 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of RAS gene expression using short interfering nucleic acid (siNA)
|
US8008472B2
(en)
|
2001-05-29 |
2011-08-30 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of human immunodeficiency virus (HIV) gene expression using short interfering nucleic acid (siNA)
|
JP4210737B2
(ja)
|
2001-07-12 |
2009-01-21 |
ユニバーシティー オブ マサチューセッツ |
遺伝子サイレンシングを仲介する低分子干渉リボ核酸のインビボにおける製造方法
|
US8022272B2
(en)
|
2001-07-13 |
2011-09-20 |
Sungene Gmbh & Co. Kgaa |
Expression cassettes for transgenic expression of nucleic acids
|
CA2452653A1
(en)
*
|
2001-07-17 |
2003-01-30 |
Anne Josephine Milner |
Silencing of gene expression by sirna
|
DK2280070T3
(en)
|
2001-07-23 |
2015-08-24 |
Univ Leland Stanford Junior |
Methods and compositions for use in RNAi-mediated inhibition of gene expression in mammals
|
US10590418B2
(en)
|
2001-07-23 |
2020-03-17 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and compositions for RNAi mediated inhibition of gene expression in mammals
|
US7456335B2
(en)
|
2001-09-03 |
2008-11-25 |
Basf Plant Science Gmbh |
Nucleic acid sequences and their use in methods for achieving pathogen resistance in plants
|
DE10163098B4
(de)
*
|
2001-10-12 |
2005-06-02 |
Alnylam Europe Ag |
Verfahren zur Hemmung der Replikation von Viren
|
US7745418B2
(en)
|
2001-10-12 |
2010-06-29 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting viral replication
|
WO2003035868A1
(de)
*
|
2001-10-26 |
2003-05-01 |
Ribopharma Ag |
Medikament zur erhöhung der wirksamkeit eines rezeptor-vermittelt apoptose in tumorzellen auslösenden arzeimittels
|
US20050119202A1
(en)
*
|
2001-10-26 |
2005-06-02 |
Roland Kreutzer |
Medicament to treat a fibrotic disease
|
DE10230996A1
(de)
*
|
2001-10-26 |
2003-07-17 |
Ribopharma Ag |
Medikament zur Behandlung eines Pankreaskarzinoms
|
DE10202419A1
(de)
|
2002-01-22 |
2003-08-07 |
Ribopharma Ag |
Verfahren zur Hemmung der Expression eines durch eine Chromosomen-Aberration entstandenen Zielgens
|
EP3415625A1
(en)
*
|
2002-02-01 |
2018-12-19 |
Life Technologies Corporation |
Double-stranded oligonucleotides
|
US20060009409A1
(en)
|
2002-02-01 |
2006-01-12 |
Woolf Tod M |
Double-stranded oligonucleotides
|
US20030166282A1
(en)
|
2002-02-01 |
2003-09-04 |
David Brown |
High potency siRNAS for reducing the expression of target genes
|
US7678897B2
(en)
|
2002-02-20 |
2010-03-16 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of platelet-derived endothelial cell growth factor (ECGF1) gene expression using short interfering nucleic acid (siNA)
|
US7897753B2
(en)
|
2002-02-20 |
2011-03-01 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of XIAP gene expression using short interfering nucleic acid (siNA)
|
US7928219B2
(en)
|
2002-02-20 |
2011-04-19 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (SINA)
|
US7691999B2
(en)
|
2002-02-20 |
2010-04-06 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of NOGO and NOGO receptor gene expression using short interfering nucleic acid (siNA)
|
US8232383B2
(en)
*
|
2002-02-20 |
2012-07-31 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
US7667029B2
(en)
|
2002-02-20 |
2010-02-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of checkpoint kinase-1 (CHK-1) gene expression using short interfering nucleic acid (siNA)
|
EP1501853A4
(en)
*
|
2002-02-20 |
2005-11-16 |
Sirna Therapeutics Inc |
RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION OF AN EPIDERMAL GROWTH FACTOR RECEPTOR USING SHORT INTERFERING NUCLEIC ACIDS
|
US8067575B2
(en)
|
2002-02-20 |
2011-11-29 |
Merck, Sharp & Dohme Corp. |
RNA interference mediated inhibition of cyclin D1 gene expression using short interfering nucleic acid (siNA)
|
US7910724B2
(en)
|
2002-02-20 |
2011-03-22 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of Fos gene expression using short interfering nucleic acid (siNA)
|
US20090192105A1
(en)
|
2002-02-20 |
2009-07-30 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF INTERCELLULAR ADHESION MOLECULE (ICAM) GENE EXPRESSION USING SHORT INTERFERING NUCELIC ACID (siNA)
|
US20090253774A1
(en)
|
2002-02-20 |
2009-10-08 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF PLATELET DERIVED GROWTH FACTOR (PDGF) AND PLATELET DERIVED GROWTH FACTOR RECEPTOR (PDGFR) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
EP1741781A3
(en)
*
|
2002-02-20 |
2007-06-06 |
Sirna Therapeutics, Inc. |
RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA)
|
US7897752B2
(en)
|
2002-02-20 |
2011-03-01 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of telomerase gene expression using short interfering nucleic acid (siNA)
|
US20090253773A1
(en)
|
2002-02-20 |
2009-10-08 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF TNF AND TNF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
EP1710307A3
(en)
*
|
2002-02-20 |
2007-06-06 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
|
US7662952B2
(en)
|
2002-02-20 |
2010-02-16 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of GRB2 associated binding protein (GAB2) gene expression using short interfering nucleic acid (siNA)
|
US8013143B2
(en)
|
2002-02-20 |
2011-09-06 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of CXCR4 gene expression using short interfering nucleic acid (siNA)
|
US8258288B2
(en)
|
2002-02-20 |
2012-09-04 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of respiratory syncytial virus (RSV) expression using short interfering nucleic acid (siNA)
|
AU2003207708A1
(en)
*
|
2002-02-20 |
2003-09-09 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of map kinase genes
|
US7667030B2
(en)
|
2002-02-20 |
2010-02-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of matrix metalloproteinase 13 (MMP13) gene expression using short interfering nucleic acid (siNA)
|
US9657294B2
(en)
|
2002-02-20 |
2017-05-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
EP1436314A4
(en)
*
|
2002-02-20 |
2005-08-10 |
Sirna Therapeutics Inc |
INHIBITION OF EXPRESSION OF THE CYCLIN D1 GENE THROUGH RNA INTERFERENCE USING SHORT INTERFERING NUCLEIC ACID (SINA)
|
EP1472265A4
(en)
*
|
2002-02-20 |
2005-06-15 |
Sirna Therapeutics Inc |
INHIBITION OF POLYCOMB GROUP PROTEIN EZH2 GENERATED BY RNA INTERFERENCE USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US9181551B2
(en)
|
2002-02-20 |
2015-11-10 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
US7683165B2
(en)
|
2002-02-20 |
2010-03-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (siNA)
|
US7897757B2
(en)
|
2002-02-20 |
2011-03-01 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of protein tyrosine phosphatase-1B (PTP-1B) gene expression using short interfering nucleic acid (siNA)
|
JP2005517450A
(ja)
*
|
2002-02-20 |
2005-06-16 |
サーナ・セラピューティクス・インコーポレイテッド |
短干渉核酸(siNA)を用いるRNA干渉媒介性標的発見および標的評価
|
US20090137510A1
(en)
*
|
2002-02-20 |
2009-05-28 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF NF-KAPPA B/ REL-A GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US7893248B2
(en)
|
2002-02-20 |
2011-02-22 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA)
|
US7795422B2
(en)
|
2002-02-20 |
2010-09-14 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of hypoxia inducible factor 1 (HIF1) gene expression using short interfering nucleic acid (siNA)
|
JP2005517423A
(ja)
*
|
2002-02-20 |
2005-06-16 |
サーナ・セラピューティクス・インコーポレイテッド |
短干渉核酸(siNA)を用いるTGF−ベータおよびTGF−ベータレセプター遺伝子の発現のRNA干渉媒介性阻害
|
CA2463595A1
(en)
*
|
2002-02-20 |
2003-08-28 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of bcl2 gene expression using short interfering nucleic acid (sina)
|
GB2397062B
(en)
|
2002-02-20 |
2005-06-15 |
Sirna Therapeutics Inc |
RNA interference mediated inhibition of hepatitis c virus (HCV) gene expression using short interfering nucleic acid (siNA)
|
US7935812B2
(en)
|
2002-02-20 |
2011-05-03 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of hepatitis C virus (HCV) expression using short interfering nucleic acid (siNA)
|
US7700760B2
(en)
|
2002-02-20 |
2010-04-20 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of vascular cell adhesion molecule (VCAM) gene expression using short interfering nucleic acid (siNA)
|
EP1476459A4
(en)
*
|
2002-02-20 |
2005-05-25 |
Sirna Therapeutics Inc |
INHIBITION OF EXPRESSION OF THE CHROMOSOME TRANSLOCATION GENE AGENT BY RNA INTERFERENCE USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US7928220B2
(en)
|
2002-02-20 |
2011-04-19 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of stromal cell-derived factor-1 (SDF-1) gene expression using short interfering nucleic acid (siNA)
|
US7683166B2
(en)
|
2002-02-20 |
2010-03-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (siNA)
|
US20090099117A1
(en)
|
2002-02-20 |
2009-04-16 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF MYOSTATIN GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
CA2477014A1
(en)
*
|
2002-02-20 |
2003-08-28 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of tnf and tnf receptor superfamily gene expression using short interfering nucleic acid (sina)
|
US20090247613A1
(en)
*
|
2002-02-20 |
2009-10-01 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF B-CELL CLL/LYMPHOMA-2 (BCL2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US7928218B2
(en)
|
2002-02-20 |
2011-04-19 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of polycomb group protein EZH2 gene expression using short interfering nucleic acid (siNA)
|
US7566813B2
(en)
|
2002-03-21 |
2009-07-28 |
Monsanto Technology, L.L.C. |
Nucleic acid constructs and methods for producing altered seed oil compositions
|
CA2479587A1
(en)
|
2002-03-21 |
2003-10-02 |
Monsanto Technology Llc |
Nucleic acid constructs and methods for producing altered seed oil compositions
|
US7166771B2
(en)
|
2002-06-21 |
2007-01-23 |
Monsanto Technology Llc |
Coordinated decrease and increase of gene expression of more than one gene using transgenic constructs
|
JP2006500910A
(ja)
|
2002-04-18 |
2006-01-12 |
アキュイティ ファーマシューティカルズ、インク. |
Cnsと眼の標的遺伝子を特異的に調節するための手段と方法及びその同定法
|
AU2003228667A1
(en)
*
|
2002-04-22 |
2003-12-19 |
Sirna Therapeutics Inc. |
Nucleic acid mediated disruption of hiv fusogenic peptide interactions
|
US20040180438A1
(en)
|
2002-04-26 |
2004-09-16 |
Pachuk Catherine J. |
Methods and compositions for silencing genes without inducing toxicity
|
CA2525976A1
(en)
|
2002-05-23 |
2003-12-04 |
Ceptyr, Inc. |
Modulation of ptp1b signal transduction by rna interference
|
US20040248094A1
(en)
*
|
2002-06-12 |
2004-12-09 |
Ford Lance P. |
Methods and compositions relating to labeled RNA molecules that reduce gene expression
|
US20100075423A1
(en)
*
|
2002-06-12 |
2010-03-25 |
Life Technologies Corporation |
Methods and compositions relating to polypeptides with rnase iii domains that mediate rna interference
|
US20040033602A1
(en)
*
|
2002-06-12 |
2004-02-19 |
Ambion, Inc. |
Methods and compositions relating to polypeptides with RNase III domains that mediate RNA interference
|
US7655790B2
(en)
|
2002-07-12 |
2010-02-02 |
Sirna Therapeutics, Inc. |
Deprotection and purification of oligonucleotides and their derivatives
|
US7148342B2
(en)
|
2002-07-24 |
2006-12-12 |
The Trustees Of The University Of Pennyslvania |
Compositions and methods for sirna inhibition of angiogenesis
|
US7399851B2
(en)
|
2002-07-25 |
2008-07-15 |
Dana Farber Cancer Institute, Inc. |
Composition and method for imaging cells
|
WO2004013333A2
(de)
|
2002-07-26 |
2004-02-12 |
Basf Plant Science Gmbh |
Revertierung der negativ-selektiven wirkung von negativen markerproteinen als selektionsverfahren
|
ATE350473T2
(de)
|
2002-08-05 |
2007-01-15 |
Atugen Ag |
Weitere neue formen von interferierende rns moleküle
|
US20040023390A1
(en)
*
|
2002-08-05 |
2004-02-05 |
Davidson Beverly L. |
SiRNA-mediated gene silencing with viral vectors
|
US20080274989A1
(en)
|
2002-08-05 |
2008-11-06 |
University Of Iowa Research Foundation |
Rna Interference Suppression of Neurodegenerative Diseases and Methods of Use Thereof
|
US20040241854A1
(en)
|
2002-08-05 |
2004-12-02 |
Davidson Beverly L. |
siRNA-mediated gene silencing
|
DK1389637T3
(da)
*
|
2002-08-05 |
2012-09-03 |
Silence Therapeutics Ag |
Interfererende RNA-molekyler med stumpe ender
|
US20050255086A1
(en)
*
|
2002-08-05 |
2005-11-17 |
Davidson Beverly L |
Nucleic acid silencing of Huntington's Disease gene
|
US20050042646A1
(en)
*
|
2002-08-05 |
2005-02-24 |
Davidson Beverly L. |
RNA interference suppresion of neurodegenerative diseases and methods of use thereof
|
WO2004018687A2
(en)
|
2002-08-07 |
2004-03-04 |
Basf Plant Science Gmbh |
Nucleic acid sequences encoding proteins associated with abiotic stress response
|
WO2004014933A1
(en)
|
2002-08-07 |
2004-02-19 |
University Of Massachusetts |
Compositions for rna interference and methods of use thereof
|
US20040029275A1
(en)
*
|
2002-08-10 |
2004-02-12 |
David Brown |
Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs
|
JP4339852B2
(ja)
|
2002-08-12 |
2009-10-07 |
ニュー・イングランド・バイオラブズ・インコーポレイティッド |
遺伝子サイレンシングに関する方法および組成物
|
EP1393742A1
(en)
|
2002-08-14 |
2004-03-03 |
atugen AG |
Use of protein kinase N beta
|
MXPA05001766A
(es)
|
2002-08-14 |
2005-08-19 |
Atugen Ag |
Uso de proteina quinasa n beta.
|
EP1551424B1
(en)
|
2002-09-04 |
2015-07-01 |
Arrowhead Research Corporation |
Treatment of chronic neuropathic pain by admistration of dsrna
|
US7923547B2
(en)
*
|
2002-09-05 |
2011-04-12 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
US20040053289A1
(en)
*
|
2002-09-09 |
2004-03-18 |
The Regents Of The University Of California |
Short interfering nucleic acid hybrids and methods thereof
|
US20040242518A1
(en)
*
|
2002-09-28 |
2004-12-02 |
Massachusetts Institute Of Technology |
Influenza therapeutic
|
CA2501752A1
(en)
|
2002-10-10 |
2004-04-22 |
Wyeth |
Compositions, organisms and methodologies employing a novel human kinase
|
ATE420102T1
(de)
|
2002-10-18 |
2009-01-15 |
Silence Therapeutics Ag |
An der metastase beteiligter faktor und verwendungen dafür
|
US7208306B2
(en)
|
2002-10-24 |
2007-04-24 |
Wyeth |
Compositions employing a novel human protein phosphatase
|
US7521431B2
(en)
|
2002-11-01 |
2009-04-21 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for siRNA inhibition of HIF-1 alpha
|
AU2003291753B2
(en)
|
2002-11-05 |
2010-07-08 |
Isis Pharmaceuticals, Inc. |
Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
|
US9150605B2
(en)
|
2002-11-05 |
2015-10-06 |
Isis Pharmaceuticals, Inc. |
Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
|
US9150606B2
(en)
|
2002-11-05 |
2015-10-06 |
Isis Pharmaceuticals, Inc. |
Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
|
AU2003291755A1
(en)
|
2002-11-05 |
2004-06-07 |
Isis Pharmaceuticals, Inc. |
Oligomers comprising modified bases for binding cytosine and uracil or thymine and their use
|
AU2003287505A1
(en)
|
2002-11-05 |
2004-06-03 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds and their use in gene modulation
|
AU2003287557A1
(en)
*
|
2002-11-07 |
2004-06-03 |
Lung-Ji Chang |
Modified dendritic cells
|
WO2006006948A2
(en)
|
2002-11-14 |
2006-01-19 |
Dharmacon, Inc. |
METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
|
US9719094B2
(en)
|
2002-11-14 |
2017-08-01 |
Thermo Fisher Scientific Inc. |
RNAi targeting SEC61G
|
US9719092B2
(en)
|
2002-11-14 |
2017-08-01 |
Thermo Fisher Scientific Inc. |
RNAi targeting CNTD2
|
US10011836B2
(en)
|
2002-11-14 |
2018-07-03 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
US9228186B2
(en)
|
2002-11-14 |
2016-01-05 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
US9771586B2
(en)
|
2002-11-14 |
2017-09-26 |
Thermo Fisher Scientific Inc. |
RNAi targeting ZNF205
|
US9839649B2
(en)
|
2002-11-14 |
2017-12-12 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
US9879266B2
(en)
|
2002-11-14 |
2018-01-30 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
CA2505416A1
(en)
|
2002-11-21 |
2004-06-10 |
Wyeth |
Methods for diagnosing rcc and other solid tumors
|
JP4526228B2
(ja)
*
|
2002-11-22 |
2010-08-18 |
隆 森田 |
RNAiによる新規治療法および治療剤
|
AU2003290664A1
(en)
|
2002-11-27 |
2004-06-23 |
Wei Liu |
Compositions, organisms and methodologies employing a novel human kinase
|
DE602004028587D1
(de)
|
2003-01-16 |
2010-09-23 |
Univ Pennsylvania |
ZUSAMMENSETZUNGEN UND VERFAHREN ZUR siRNA-HEMMUNG VON ICAM-1
|
JP2007524362A
(ja)
|
2003-02-14 |
2007-08-30 |
サイグレス ディスカバリー, インコーポレイテッド |
癌における治療gpcr標的
|
WO2004080406A2
(en)
|
2003-03-07 |
2004-09-23 |
Alnylam Pharmaceuticals |
Therapeutic compositions
|
DK1606406T4
(da)
|
2003-03-21 |
2013-12-16 |
Santaris Pharma As |
Short Interfering RNA (siRNA) Analogues
|
AU2004229519B2
(en)
|
2003-04-09 |
2011-07-21 |
Alnylam Pharmaceuticals, Inc. |
iRNA conjugates
|
US20090298914A1
(en)
*
|
2003-04-15 |
2009-12-03 |
Sirna Therapeutics, Inc. |
RNA Interference Mediated Inhibition of Severe Acute Respiratory Syndrome (SARS) Virus Gene Expression Using Short Interfering Nucleic Acid (siNA)
|
US20070270360A1
(en)
*
|
2003-04-15 |
2007-11-22 |
Sirna Therapeutics, Inc. |
Rna Interference Mediated Inhibition of Severe Acute Respiratory Syndrome (Sars) Gene Expression Using Short Interfering Nucleic Acid
|
EP2666858A1
(en)
|
2003-04-17 |
2013-11-27 |
Alnylam Pharmaceuticals Inc. |
Modified iRNA agents
|
CA2522349A1
(en)
|
2003-04-17 |
2004-11-04 |
Alnylam Pharmaceuticals, Inc. |
Protected monomers
|
US7723509B2
(en)
|
2003-04-17 |
2010-05-25 |
Alnylam Pharmaceuticals |
IRNA agents with biocleavable tethers
|
US8796436B2
(en)
|
2003-04-17 |
2014-08-05 |
Alnylam Pharmaceuticals, Inc. |
Modified iRNA agents
|
US7851615B2
(en)
|
2003-04-17 |
2010-12-14 |
Alnylam Pharmaceuticals, Inc. |
Lipophilic conjugated iRNA agents
|
US8017762B2
(en)
|
2003-04-17 |
2011-09-13 |
Alnylam Pharmaceuticals, Inc. |
Modified iRNA agents
|
EP1615943A4
(en)
|
2003-04-18 |
2006-08-16 |
Univ Pennsylvania |
COMPOSITIONS AND METHODS FOR INHIBITING ARNIC OF ANGIOPOIETIN 1 AND 2 AND THEIR TIE2 RECEPTOR
|
EP1622572B1
(en)
|
2003-04-30 |
2017-12-20 |
Sirna Therapeutics, Inc. |
Conjugates and compositions for cellular delivery
|
CA2524495A1
(en)
|
2003-06-03 |
2005-01-13 |
Eli Lilly And Company |
Modulation of survivin expression
|
US7595306B2
(en)
|
2003-06-09 |
2009-09-29 |
Alnylam Pharmaceuticals Inc |
Method of treating neurodegenerative disease
|
DK3604537T3
(da)
|
2003-06-13 |
2022-02-28 |
Alnylam Europe Ag |
Dobbeltstrenget ribonukleinsyre med forøget effektivitet i en organisme
|
EP1644496A4
(en)
*
|
2003-06-25 |
2006-10-04 |
Gencia Corp |
MODIFIED VECTORS FOR ORGANIC TRANSFECTION
|
WO2005007859A2
(en)
*
|
2003-07-11 |
2005-01-27 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF ACETYL-COA CARBOXYLASE GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
EP1654368A2
(en)
|
2003-08-01 |
2006-05-10 |
BASF Plant Science GmbH |
Process for the production of fine chemicals
|
EP2489737A1
(en)
|
2003-08-28 |
2012-08-22 |
Novartis AG |
Interfering RNA duplex having blunt-ends and 3'-modifications
|
US20070202505A1
(en)
*
|
2003-09-08 |
2007-08-30 |
Alex Chenchik |
Methods for gene function analysis
|
WO2005045037A2
(en)
*
|
2003-10-23 |
2005-05-19 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF 5-ALPHA REDUCTASE AND ANDROGEN RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
ATE503014T1
(de)
*
|
2003-11-04 |
2011-04-15 |
Geron Corp |
Rna-amidate und thioamidateur rnai
|
GB2424887B
(en)
*
|
2003-11-26 |
2008-05-21 |
Univ Massachusetts |
Sequence-specific inhibition of small RNA function
|
JP4682152B2
(ja)
|
2003-12-31 |
2011-05-11 |
ザ・ペン・ステート・リサーチ・ファンデーション |
卵巣がんの化学療法に対する抵抗性を予測および克服するための方法ならびに結腸がんの発生を予測するための方法
|
WO2005073378A1
(en)
*
|
2004-01-30 |
2005-08-11 |
Santaris Pharma A/S |
MODIFIED SHORT INTERFERING RNA (MODIFIED siRNA)
|
EP2330111A3
(en)
|
2004-01-30 |
2011-08-17 |
Quark Pharmaceuticals, Inc. |
Oligoribonucleotides and methods of use thereof for treatment of fibrotic conditions and other diseases
|
US20090280567A1
(en)
*
|
2004-02-06 |
2009-11-12 |
Dharmacon, Inc. |
Stabilized sirnas as transfection controls and silencing reagents
|
EP2123759B1
(en)
*
|
2004-02-06 |
2014-01-15 |
Thermo Fisher Scientific Biosciences Inc. |
Stabilized RNAS as transfection controls and silencing reagents
|
US7655402B2
(en)
|
2004-02-06 |
2010-02-02 |
Wyeth Llc |
Diagnoses and therapeutics for cancer
|
CA2554212A1
(en)
|
2004-02-10 |
2005-08-25 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of gene expression using multifunctional short interfering nucleic acid (multifunctional sina)
|
WO2005078848A2
(en)
|
2004-02-11 |
2005-08-25 |
University Of Tennessee Research Foundation |
Inhibition of tumor growth and invasion by anti-matrix metalloproteinase dnazymes
|
JP2007523956A
(ja)
|
2004-02-25 |
2007-08-23 |
ダナ−ファーバー キャンサー インスティテュート インク. |
腫瘍細胞増殖を阻害するための方法
|
EP2636739B1
(en)
|
2004-03-12 |
2014-12-10 |
Alnylam Pharmaceuticals Inc. |
iRNA agents targeting VEGF
|
KR101147147B1
(ko)
*
|
2004-04-01 |
2012-05-25 |
머크 샤프 앤드 돔 코포레이션 |
Rna 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
|
JP5223072B2
(ja)
|
2004-04-02 |
2013-06-26 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
avβ5インテグリンに関連のある疾患を治療および予防するための方法および組成物
|
CA2557532A1
(en)
|
2004-04-23 |
2005-11-10 |
Angela M. Christiano |
Inhibition of hairless protein mrna
|
DE102004025881A1
(de)
|
2004-05-19 |
2006-01-05 |
Beiersdorf Ag |
Oligoribonukleotide zur Beeinflussung des Haarwachstums
|
US10508277B2
(en)
|
2004-05-24 |
2019-12-17 |
Sirna Therapeutics, Inc. |
Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
|
EP2290071B1
(en)
|
2004-05-28 |
2014-12-31 |
Asuragen, Inc. |
Methods and compositions involving microRNA
|
US8394947B2
(en)
|
2004-06-03 |
2013-03-12 |
Isis Pharmaceuticals, Inc. |
Positionally modified siRNA constructs
|
EP1602926A1
(en)
|
2004-06-04 |
2005-12-07 |
University of Geneva |
Novel means and methods for the treatment of hearing loss and phantom hearing
|
US20060003410A1
(en)
|
2004-06-10 |
2006-01-05 |
Lee-Ming Chuang |
Prostaglandin reductase
|
EP1758999B1
(en)
|
2004-06-22 |
2011-03-09 |
The Board Of Trustees Of The University Of Illinois |
METHODS OF INHIBITING TUMOR CELL PROLIFERATION WITH FOXM1 siRNA
|
WO2006002538A1
(en)
|
2004-07-02 |
2006-01-12 |
Protiva Biotherapeutics, Inc. |
Immunostimulatory sirna molecules and uses therefor
|
EP2080769A3
(en)
|
2004-07-02 |
2010-12-01 |
Metanomics GmbH |
Process for the production of fine chemicals
|
US7968762B2
(en)
|
2004-07-13 |
2011-06-28 |
Van Andel Research Institute |
Immune-compromised transgenic mice expressing human hepatocyte growth factor (hHGF)
|
US20060024677A1
(en)
|
2004-07-20 |
2006-02-02 |
Morris David W |
Novel therapeutic targets in cancer
|
EP2484780A1
(en)
|
2004-07-23 |
2012-08-08 |
The University of North Carolina At Chapel Hill |
Methods and materials for determining pain sensibility and predicting and treating related disorders
|
CN101001951B
(zh)
|
2004-08-02 |
2011-06-15 |
巴斯福植物科学有限公司 |
分离转录终止序列的方法
|
JP5060293B2
(ja)
|
2004-08-03 |
2012-10-31 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
神経機能におけるtaj
|
CA2576233C
(en)
|
2004-08-10 |
2016-03-15 |
Alnylam Pharmaceuticals, Inc. |
Conjugate comprising an antagomir and a ligand
|
AP2007003921A0
(en)
|
2004-08-16 |
2007-02-28 |
Atugen Ag |
Therapeutic uses of inhibitors of rtp801
|
ATE518954T1
(de)
|
2004-08-18 |
2011-08-15 |
Lorus Therapeutics Inc |
Kleine interferierende rna-moleküle gegen ribonukleotidreduktase und ihre verwendungen
|
US7884086B2
(en)
|
2004-09-08 |
2011-02-08 |
Isis Pharmaceuticals, Inc. |
Conjugates for use in hepatocyte free uptake assays
|
US20090170794A1
(en)
|
2004-09-10 |
2009-07-02 |
Somagenics Inc. |
Small interfering rnas that efficiently inhibit viral expression and methods of use thereof
|
CA2579927A1
(en)
|
2004-09-24 |
2006-03-30 |
Basf Plant Science Gmbh |
Plant cells and plants with increased tolerance to environmental stress
|
DK1799269T3
(en)
|
2004-09-28 |
2016-10-03 |
Quark Pharmaceuticals Inc |
Oligoribonucleotides and methods of use thereof for treating alopecia, acute renal failure, and other diseases
|
EP2166097B1
(en)
|
2004-10-05 |
2014-08-06 |
SunGene GmbH |
Constitutive expression cassettes for regulation of plant expression
|
CA2583722C
(en)
|
2004-10-13 |
2012-04-24 |
University Of Georgia Research Foundation, Inc. |
Nematode resistant transgenic plants
|
US9492400B2
(en)
|
2004-11-04 |
2016-11-15 |
Massachusetts Institute Of Technology |
Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
|
EP1655364A3
(en)
|
2004-11-05 |
2006-08-02 |
BASF Plant Science GmbH |
Expression cassettes for seed-preferential expression in plants
|
WO2006137941A2
(en)
|
2004-11-12 |
2006-12-28 |
Ambion, Inc. |
Methods and compositions involving mirna and mirna inhibitor molecules
|
US7923206B2
(en)
*
|
2004-11-22 |
2011-04-12 |
Dharmacon, Inc. |
Method of determining a cellular response to a biological agent
|
US7935811B2
(en)
*
|
2004-11-22 |
2011-05-03 |
Dharmacon, Inc. |
Apparatus and system having dry gene silencing compositions
|
US7923207B2
(en)
|
2004-11-22 |
2011-04-12 |
Dharmacon, Inc. |
Apparatus and system having dry gene silencing pools
|
EP2163631B1
(en)
|
2004-11-25 |
2013-05-22 |
SunGene GmbH |
Expression cassettes for guard cell-preferential expression in plants
|
EP1666599A3
(en)
|
2004-12-04 |
2006-07-12 |
SunGene GmbH |
Expression cassettes for mesophyll- and/or epidermis-preferential expression in plants
|
EP2072620B1
(en)
|
2004-12-08 |
2013-05-08 |
SunGene GmbH |
Expression casstettes for vascular tissue-preferential expression in plants
|
EP1669456A3
(en)
|
2004-12-11 |
2006-07-12 |
SunGene GmbH |
Expression cassettes for meristem-preferential expression in plants
|
MX2007007040A
(es)
|
2004-12-17 |
2008-10-24 |
Metanomics Gmbh |
Proceso para el control de produccion de productos quimicos finos.
|
TWI386225B
(zh)
|
2004-12-23 |
2013-02-21 |
Alcon Inc |
用於治療眼睛病症的結締組織生長因子(CTGF)RNA干擾(RNAi)抑制技術
|
US20060142228A1
(en)
*
|
2004-12-23 |
2006-06-29 |
Ambion, Inc. |
Methods and compositions concerning siRNA's as mediators of RNA interference
|
EP2992902A1
(en)
|
2004-12-27 |
2016-03-09 |
Silence Therapeutics GmbH |
Lipid complexes coated with peg and their uses
|
JP2008526213A
(ja)
*
|
2004-12-30 |
2008-07-24 |
トッド エム. ハウザー, |
自己保護オリゴヌクレオチドを使用する、遺伝子発現を調節するための組成物および方法
|
WO2006072887A1
(en)
|
2005-01-05 |
2006-07-13 |
Eyegate Pharma Sa |
Ocular iontophoresis device for delivering sirna and aptamers
|
EP2230517A1
(en)
|
2005-01-07 |
2010-09-22 |
Diadexus, Inc. |
OVR110 antibody compositions and methods of use
|
TW200639253A
(en)
|
2005-02-01 |
2006-11-16 |
Alcon Inc |
RNAi-mediated inhibition of ocular targets
|
WO2006084868A2
(en)
|
2005-02-09 |
2006-08-17 |
Basf Plant Science Gmbh |
Expression cassettes for regulation of expression in monocotyledonous plants
|
CN101128591B
(zh)
|
2005-02-26 |
2013-02-13 |
巴斯福植物科学有限公司 |
用于植物中种子偏好性表达的表达盒
|
US8084625B2
(en)
|
2005-03-03 |
2011-12-27 |
Wako Pure Chemical Industries, Ltd. |
Crosslinking agent, crosslinking method, method of controlling gene expression, and method of examining gene function
|
EP2166100B1
(en)
|
2005-03-08 |
2012-07-18 |
BASF Plant Science GmbH |
Expression enhancing intron sequences
|
AU2006223131A1
(en)
|
2005-03-11 |
2006-09-21 |
Alcon, Inc. |
RNAi-mediated inhibition of frizzled related protein-1 for treatment of glaucoma
|
US20060223777A1
(en)
*
|
2005-03-29 |
2006-10-05 |
Dharmacon, Inc. |
Highly functional short hairpin RNA
|
CA2603730A1
(en)
|
2005-03-31 |
2006-10-05 |
Calando Pharmaceuticals, Inc. |
Inhibitors of ribonucleotide reductase subunit 2 and uses thereof
|
AU2006235258A1
(en)
|
2005-04-07 |
2006-10-19 |
Novartis Vaccines And Diagnostics Inc. |
Cancer-related genes
|
CA2604885A1
(en)
|
2005-04-07 |
2006-10-19 |
Guoying Yu |
Cacna1e in cancer diagnosis, detection and treatment
|
JP4967137B2
(ja)
*
|
2005-04-18 |
2012-07-04 |
国立大学法人浜松医科大学 |
癌治療用組成物
|
WO2006113743A2
(en)
*
|
2005-04-18 |
2006-10-26 |
Massachusetts Institute Of Technology |
Compositions and methods for rna interference with sialidase expression and uses thereof
|
WO2006120197A2
(en)
|
2005-05-10 |
2006-11-16 |
Basf Plant Science Gmbh |
Expression cassettes for seed-preferential expression in plants
|
CA2605508A1
(en)
*
|
2005-05-12 |
2006-11-23 |
Wisconsin Alumni Research Foundation |
Blockade of pin1 prevents cytokine production by activated immune cells
|
FR2885808B1
(fr)
|
2005-05-19 |
2007-07-06 |
Oreal |
Vectorisation de dsrna par des particules cationiques et utilisation topique.
|
BRPI0612671A2
(pt)
|
2005-06-23 |
2010-11-30 |
Basf Plant Science Gmbh |
métodos melhorados para a produção de plantas férteis zea mays (milho) estavelmente transformadas
|
WO2007011702A2
(en)
|
2005-07-15 |
2007-01-25 |
The University Of North Carolina At Chapel Hill |
Use of egfr inhibitors to prevent or treat obesity
|
EP1764107A1
(en)
*
|
2005-09-14 |
2007-03-21 |
Gunther Hartmann |
Compositions comprising immunostimulatory RNA oligonucleotides and methods for producing said RNA oligonucleotides
|
EP2980220A1
(en)
|
2005-09-20 |
2016-02-03 |
BASF Plant Science GmbH |
Improved methods controlling gene expression
|
US8093369B2
(en)
|
2005-10-11 |
2012-01-10 |
Ben Gurion University Of The Negev Research And Development Authority Ltd. |
Compositions for silencing the expression of VDAC1 and uses thereof
|
AU2006305886C1
(en)
|
2005-10-28 |
2011-03-17 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of huntingtin gene
|
EP2395012B8
(en)
|
2005-11-02 |
2018-06-06 |
Arbutus Biopharma Corporation |
Modified siRNA molecules and uses thereof
|
EP1942948A4
(en)
|
2005-11-04 |
2010-03-03 |
Alnylam Pharmaceuticals Inc |
COMPOSITIONS AND METHODS FOR INHIBITING THE EXPRESSION OF THE NAV1.8 GENE
|
CA2628505A1
(en)
|
2005-11-08 |
2007-05-18 |
Basf Plant Science Gmbh |
Use of armadillo repeat (arm1) polynucleotides for obtaining resistance to pathogens in plants
|
AU2006311730B2
(en)
|
2005-11-09 |
2010-12-02 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of Factor V Leiden mutant gene
|
US20070166738A1
(en)
|
2005-11-29 |
2007-07-19 |
Perlegen Sciences, Inc. |
Markers for breast cancer
|
WO2007070682A2
(en)
|
2005-12-15 |
2007-06-21 |
Massachusetts Institute Of Technology |
System for screening particles
|
MX2008008548A
(es)
|
2005-12-30 |
2008-09-10 |
Evonik Roehm Gmbh |
Peptidos utiles como petidos penetradores de celulas.
|
EP1974041A2
(en)
|
2006-01-06 |
2008-10-01 |
University Of Georgia Research Foundation, Inc. |
Cyst nematode resistant transgenic plants
|
ES2464315T3
(es)
|
2006-01-12 |
2014-06-02 |
Basf Plant Science Gmbh |
Uso de polinucleótidos de estomatina (STM1) para alcanzar una resistencia a patógenos en plantas
|
UY30097A1
(es)
|
2006-01-20 |
2007-08-31 |
Atugen Ag |
Usos terapeuticos de inhibidores de rtp801
|
US7825099B2
(en)
|
2006-01-20 |
2010-11-02 |
Quark Pharmaceuticals, Inc. |
Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes
|
WO2007089601A2
(en)
|
2006-01-27 |
2007-08-09 |
Biogen Idec Ma Inc. |
Nogo receptor antagonists
|
AU2007209481B2
(en)
*
|
2006-01-27 |
2012-01-12 |
Roche Innovation Center Copenhagen A/S |
LNA modified phosphorothiolated oligonucleotides
|
CN101421406B
(zh)
|
2006-02-13 |
2016-08-31 |
孟山都技术有限公司 |
用于产生改变的种子油组成的核酸构建体和方法
|
US7910566B2
(en)
|
2006-03-09 |
2011-03-22 |
Quark Pharmaceuticals Inc. |
Prevention and treatment of acute renal failure and other kidney diseases by inhibition of p53 by siRNA
|
ES2556128T3
(es)
|
2006-03-23 |
2016-01-13 |
Roche Innovation Center Copenhagen A/S |
ARN interfiriente pequeño internamente segmentado
|
FR2898908A1
(fr)
|
2006-03-24 |
2007-09-28 |
Agronomique Inst Nat Rech |
Procede de preparation de cellules aviaires differenciees et genes impliques dans le maintien de la pluripotence
|
WO2007123777A2
(en)
|
2006-03-30 |
2007-11-01 |
Duke University |
Inhibition of hif-1 activation for anti-tumor and anti-inflammatory responses
|
EP2008274B1
(en)
|
2006-03-31 |
2015-05-27 |
Alnylam Pharmaceuticals Inc. |
Compositions and methods for inhibiting expression of eg5 gene
|
CA2644273A1
(en)
|
2006-04-05 |
2008-03-27 |
Metanomics Gmbh |
Process for the production of a fine chemical
|
EP2407483A1
(en)
|
2006-04-13 |
2012-01-18 |
Novartis Vaccines and Diagnostics, Inc. |
Methods of treating, diagnosing or detecting cancers
|
WO2007127919A2
(en)
|
2006-04-28 |
2007-11-08 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a gene from the jc virus
|
GB0608838D0
(en)
|
2006-05-04 |
2006-06-14 |
Novartis Ag |
Organic compounds
|
CN101484588B
(zh)
|
2006-05-11 |
2013-11-06 |
阿尔尼拉姆医药品有限公司 |
抑制pcsk9基因表达的组合物和方法
|
US8367113B2
(en)
|
2006-05-15 |
2013-02-05 |
Massachusetts Institute Of Technology |
Polymers for functional particles
|
US7812150B2
(en)
|
2006-05-19 |
2010-10-12 |
Alnylam Pharmaceuticals, Inc. |
RNAi modulation of Aha and therapeutic uses thereof
|
EP2018443A4
(en)
|
2006-05-22 |
2009-11-11 |
Alnylam Pharmaceuticals Inc |
COMPOSITIONS AND METHODS INHIBITING EXPRESSION OF IKK-B GENE
|
EP2026843A4
(en)
|
2006-06-09 |
2011-06-22 |
Quark Pharmaceuticals Inc |
THERAPEUTIC USES OF RTP801L INHIBITORS
|
US7915399B2
(en)
|
2006-06-09 |
2011-03-29 |
Protiva Biotherapeutics, Inc. |
Modified siRNA molecules and uses thereof
|
WO2007150030A2
(en)
|
2006-06-23 |
2007-12-27 |
Massachusetts Institute Of Technology |
Microfluidic synthesis of organic nanoparticles
|
US7981866B2
(en)
|
2006-07-11 |
2011-07-19 |
University Of Medicine And Dentistry Of New Jersey |
MG53 compositions and methods of use
|
CN102321626B
(zh)
|
2006-07-21 |
2014-12-10 |
赛伦斯治疗有限公司 |
用于抑制蛋白激酶3表达的方法
|
AU2007279205B2
(en)
|
2006-07-28 |
2013-09-26 |
Children's Memorial Hospital |
Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells
|
US7872118B2
(en)
|
2006-09-08 |
2011-01-18 |
Opko Ophthalmics, Llc |
siRNA and methods of manufacture
|
EP2069380B1
(en)
|
2006-09-18 |
2014-11-12 |
Alnylam Pharmaceuticals Inc. |
Rnai modulation of scap and therapeutic uses thereof
|
AU2007299629C1
(en)
|
2006-09-21 |
2012-05-10 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the HAMP gene
|
US8252755B2
(en)
*
|
2006-09-22 |
2012-08-28 |
Dharmacon, Inc. |
Duplex oligonucleotide complexes and methods for gene silencing by RNA interference
|
JP2010507387A
(ja)
|
2006-10-25 |
2010-03-11 |
クアーク・ファーマスーティカルス、インコーポレイテッド |
新規のsiRNAおよびその使用方法
|
DE602007014389D1
(de)
*
|
2006-11-01 |
2011-06-16 |
Medical Res And Infrastructure Fund Of The Tel Aviv |
Adipozytenspezifische konstrukte und verfahren zur hemmung der expression von blutplättchen-typ-12-lipoxygenase
|
CA2683287A1
(en)
|
2006-11-27 |
2008-12-18 |
Patrys Limited |
Novel glycosylated peptide target in neoplastic cells
|
WO2008067283A2
(en)
|
2006-11-27 |
2008-06-05 |
Diadexus, Inc. |
Ovr110 antibody compositions and methods of use
|
EP2913341A1
(en)
|
2006-12-22 |
2015-09-02 |
University of Utah Research Foundation |
Method of detecting ocular diseases and pathologic conditions and treatment of same
|
WO2008087141A2
(en)
|
2007-01-15 |
2008-07-24 |
Basf Plant Science Gmbh |
Use of subtilisin (rnr9) polynucleotides for achieving a pathogen resistance in plants
|
US8455188B2
(en)
|
2007-01-26 |
2013-06-04 |
University Of Louisville Research Foundation, Inc. |
Modification of exosomal components for use as a vaccine
|
US9217129B2
(en)
|
2007-02-09 |
2015-12-22 |
Massachusetts Institute Of Technology |
Oscillating cell culture bioreactor
|
WO2008099013A1
(en)
|
2007-02-16 |
2008-08-21 |
Basf Plant Science Gmbh |
Nucleic acid sequences for regulation of embryo-specific expression in monocotyledonous plants
|
US7872119B2
(en)
|
2007-02-26 |
2011-01-18 |
Quark Pharmaceuticals, Inc. |
Inhibitors of RTP801 and their use in disease treatment
|
EP2474556A3
(en)
|
2007-03-14 |
2012-10-17 |
Novartis AG |
APCDD1 inhibitors for treating, diagnosing or detecting cancer
|
AU2008228814B2
(en)
|
2007-03-21 |
2014-03-06 |
Brookhaven Science Associates, Llc |
Combined hairpin-antisense compositions and methods for modulating expression
|
US7812002B2
(en)
|
2007-03-21 |
2010-10-12 |
Quark Pharmaceuticals, Inc. |
Oligoribonucleotide inhibitors of NRF2 and methods of use thereof for treatment of cancer
|
PE20090064A1
(es)
|
2007-03-26 |
2009-03-02 |
Novartis Ag |
Acido ribonucleico de doble cadena para inhibir la expresion del gen e6ap humano y composicion farmaceutica que lo comprende
|
EP2905336A1
(en)
|
2007-03-29 |
2015-08-12 |
Alnylam Pharmaceuticals Inc. |
Compositions and methods for inhibiting expression of a gene from the ebola
|
WO2008124632A1
(en)
|
2007-04-04 |
2008-10-16 |
Massachusetts Institute Of Technology |
Amphiphilic compound assisted nanoparticles for targeted delivery
|
WO2008131129A2
(en)
|
2007-04-17 |
2008-10-30 |
Baxter International Inc. |
Nucleic acid microparticles for pulmonary delivery
|
WO2009014565A2
(en)
|
2007-04-26 |
2009-01-29 |
Ludwig Institute For Cancer Research, Ltd. |
Methods for diagnosing and treating astrocytomas
|
EP2155860B1
(en)
|
2007-05-03 |
2014-08-27 |
The Brigham and Women's Hospital, Inc. |
Multipotent stem cells and uses thereof
|
JP5296328B2
(ja)
|
2007-05-09 |
2013-09-25 |
独立行政法人理化学研究所 |
1本鎖環状rnaおよびその製造方法
|
ES2573936T3
(es)
|
2007-05-22 |
2016-06-13 |
Arcturus Therapeutics, Inc. |
Oligómeros para agentes terapéuticos
|
US20100162432A1
(en)
|
2007-05-22 |
2010-06-24 |
Basf Plant Science Gmbh |
Plant cells and plants with increased tolerance and/or resistance to environmental stress and increased biomass production-ko
|
US8097422B2
(en)
|
2007-06-20 |
2012-01-17 |
Salk Institute For Biological Studies |
Kir channel modulators
|
EP2170403B1
(en)
|
2007-06-27 |
2014-04-16 |
Quark Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of pro-apoptotic genes
|
EP2316943B1
(en)
|
2007-07-05 |
2013-06-19 |
Novartis AG |
DSRNA for treating viral infection
|
US9689031B2
(en)
|
2007-07-14 |
2017-06-27 |
Ionian Technologies, Inc. |
Nicking and extension amplification reaction for the exponential amplification of nucleic acids
|
WO2009012263A2
(en)
|
2007-07-18 |
2009-01-22 |
The Trustees Of Columbia University In The City Of New York |
Tissue-specific micrornas and compositions and uses thereof
|
EP2185719B1
(en)
|
2007-08-02 |
2013-11-13 |
NovImmune SA |
Anti-rantes antibodies and methods of use thereof
|
JP2010536852A
(ja)
|
2007-08-23 |
2010-12-02 |
ザ ボード オブ トラスティーズ オブ ザ リランド スタンフォード ジュニア ユニヴァーシティ |
シナプス形成の調節
|
US8183221B2
(en)
|
2007-09-05 |
2012-05-22 |
Medtronic, Inc. |
Suppression of SCN9A gene expression and/or function for the treatment of pain
|
US8361714B2
(en)
|
2007-09-14 |
2013-01-29 |
Asuragen, Inc. |
Micrornas differentially expressed in cervical cancer and uses thereof
|
EP2190995A2
(en)
*
|
2007-09-18 |
2010-06-02 |
Intradigm Corporation |
Compositions comprising k-ras sirna and methods of use
|
WO2009039300A2
(en)
*
|
2007-09-18 |
2009-03-26 |
Intradigm Corporation |
Compositions comprising hif-1 alpha sirna and methods of use thereof
|
EP2548962B1
(en)
|
2007-09-19 |
2016-01-13 |
Applied Biosystems, LLC |
Sirna sequence-independent modification formats for reducing off-target phenotypic effects in rnai, and stabilized forms thereof
|
HUE035101T2
(hu)
|
2007-09-28 |
2018-05-02 |
Pfizer |
Ráksejtek célzása nanorészecskék alkalmazásával
|
JP5646997B2
(ja)
|
2007-10-03 |
2014-12-24 |
クォーク ファーマシューティカルズ インコーポレーティッドQuark Pharmaceuticals,Inc. |
新規siRNA構造
|
MX350501B
(es)
|
2007-10-12 |
2017-09-07 |
Massachusetts Inst Technology |
Nanotecnologia de vacuna.
|
US8097712B2
(en)
|
2007-11-07 |
2012-01-17 |
Beelogics Inc. |
Compositions for conferring tolerance to viral disease in social insects, and the use thereof
|
EP2231195B1
(en)
|
2007-12-04 |
2017-03-29 |
Arbutus Biopharma Corporation |
Targeting lipids
|
AU2008335202A1
(en)
|
2007-12-10 |
2009-06-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of Factor VII gene
|
US20100204305A1
(en)
*
|
2007-12-11 |
2010-08-12 |
Lorus Therapeutics Inc. |
Small interfering rna molecules against ribonucleotide reductase and uses thereof
|
US8614311B2
(en)
|
2007-12-12 |
2013-12-24 |
Quark Pharmaceuticals, Inc. |
RTP801L siRNA compounds and methods of use thereof
|
DE112008003433T5
(de)
|
2007-12-21 |
2010-11-04 |
Basf Plant Science Gmbh |
Pflanzen mit erhöhtem Ertrag (KO NUE)
|
WO2009090639A2
(en)
*
|
2008-01-15 |
2009-07-23 |
Quark Pharmaceuticals, Inc. |
Sirna compounds and methods of use thereof
|
US8188060B2
(en)
|
2008-02-11 |
2012-05-29 |
Dharmacon, Inc. |
Duplex oligonucleotides with enhanced functionality in gene regulation
|
CN104975020B
(zh)
|
2008-02-11 |
2020-01-17 |
菲奥医药公司 |
经修饰的RNAi多核苷酸及其用途
|
CN102014932B
(zh)
|
2008-03-05 |
2015-11-25 |
阿尔尼拉姆医药品有限公司 |
用于抑制Eg5和VEGF基因表达的组合物和方法
|
CA2717496A1
(en)
*
|
2008-03-12 |
2009-09-17 |
Intradigm Corporation |
Compositions comprising notch1 sirna and methods of use thereof
|
BRPI0911332A2
(pt)
|
2008-04-04 |
2019-09-24 |
Calando Pharmaceuticals Inc |
composições e uso de inibidores de epas1
|
AU2009234266B2
(en)
|
2008-04-11 |
2015-08-06 |
Tekmira Pharmaceuticals Corporation |
Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
|
US8278287B2
(en)
|
2008-04-15 |
2012-10-02 |
Quark Pharmaceuticals Inc. |
siRNA compounds for inhibiting NRF2
|
GB0807018D0
(en)
|
2008-04-17 |
2008-05-21 |
Fusion Antibodies Ltd |
Antibodies and treatment
|
EP2990487A1
(en)
|
2008-05-08 |
2016-03-02 |
Asuragen, INC. |
Compositions and methods related to mirna modulation of neovascularization or angiogenesis
|
JP5524189B2
(ja)
|
2008-06-06 |
2014-06-18 |
クォーク ファーマシューティカルズ インコーポレーティッド |
耳障害治療のための組成物および方法
|
TWI455944B
(zh)
|
2008-07-01 |
2014-10-11 |
Daiichi Sankyo Co Ltd |
雙股多核苷酸
|
WO2010008582A2
(en)
|
2008-07-18 |
2010-01-21 |
Rxi Pharmaceuticals Corporation |
Phagocytic cell drug delivery system
|
WO2011011027A1
(en)
|
2009-07-20 |
2011-01-27 |
Bristol-Myers Squibb Company |
Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
|
EP2326351B1
(en)
|
2008-08-19 |
2017-12-27 |
Nektar Therapeutics |
Conjugates of small-interfering nucleic acids
|
WO2011028218A1
(en)
|
2009-09-02 |
2011-03-10 |
Alnylam Pharmaceuticals, Inc. |
Process for triphosphate oligonucleotide synthesis
|
EP2690175B1
(en)
|
2008-09-02 |
2016-12-28 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for combined inhibition of mutant EGFR gene and IL-6 expression
|
EP2165710A1
(en)
|
2008-09-19 |
2010-03-24 |
Institut Curie |
Tyrosine kinase receptor Tyro3 as a therapeutic target in the treatment of a bladder tumor
|
US10138485B2
(en)
|
2008-09-22 |
2018-11-27 |
Rxi Pharmaceuticals Corporation |
Neutral nanotransporters
|
WO2010039548A2
(en)
|
2008-09-23 |
2010-04-08 |
Alnylam Pharmaceuticals, Inc. |
Chemical modifications of monomers and oligonucleotides with cycloaddition
|
EP2334793B1
(en)
|
2008-09-25 |
2016-04-06 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of serum amyloid a gene
|
UY32145A
(es)
|
2008-09-29 |
2010-04-30 |
Monsanto Technology Llc |
Evento transgénico de soja mon87705 y métodos para detectar el mismo
|
US8591905B2
(en)
|
2008-10-12 |
2013-11-26 |
The Brigham And Women's Hospital, Inc. |
Nicotine immunonanotherapeutics
|
US8343497B2
(en)
|
2008-10-12 |
2013-01-01 |
The Brigham And Women's Hospital, Inc. |
Targeting of antigen presenting cells with immunonanotherapeutics
|
US8277812B2
(en)
|
2008-10-12 |
2012-10-02 |
Massachusetts Institute Of Technology |
Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
|
US8343498B2
(en)
|
2008-10-12 |
2013-01-01 |
Massachusetts Institute Of Technology |
Adjuvant incorporation in immunonanotherapeutics
|
JP2012505657A
(ja)
*
|
2008-10-15 |
2012-03-08 |
ソマジェニックス インク. |
遺伝子発現の阻害のためのショートヘアピンrna
|
CA3018487A1
(en)
|
2008-10-20 |
2010-04-29 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of transthyretin
|
WO2010054221A2
(en)
|
2008-11-06 |
2010-05-14 |
The Johns Hopkins University |
Treatment of chronic inflammatory respiratory disorders
|
CA3039251C
(en)
|
2008-11-10 |
2024-01-09 |
Arbutus Biopharma Corporation |
Novel lipids and compositions for the delivery of therapeutics
|
EP2687609B1
(en)
|
2008-11-10 |
2017-01-04 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Method for treating solid tumor
|
US9074211B2
(en)
|
2008-11-19 |
2015-07-07 |
Rxi Pharmaceuticals Corporation |
Inhibition of MAP4K4 through RNAI
|
JP5816556B2
(ja)
|
2008-12-03 |
2015-11-18 |
アークトゥラス・セラピューティクス・インコーポレイテッドArcturus Therapeutics,Inc. |
治療剤のためのunaオリゴマー構造
|
CA2745832A1
(en)
|
2008-12-04 |
2010-06-10 |
Opko Ophthalmics, Llc |
Compositions and methods for selective inhibition of pro-angiogenic vegf isoforms
|
CA2746514C
(en)
|
2008-12-10 |
2018-11-27 |
Alnylam Pharmaceuticals, Inc. |
Gnaq targeted dsrna compositions and methods for inhibiting expression
|
EP2198879A1
(en)
|
2008-12-11 |
2010-06-23 |
Institut Curie |
CD74 modulator agent for regulating dendritic cell migration and device for studying the motility capacity of a cell
|
US20100233172A1
(en)
|
2008-12-16 |
2010-09-16 |
Bristol-Myers Squibb Company |
Methods of inhibiting quiescent tumor proliferation
|
WO2010080452A2
(en)
|
2008-12-18 |
2010-07-15 |
Quark Pharmaceuticals, Inc. |
siRNA COMPOUNDS AND METHODS OF USE THEREOF
|
WO2010074783A1
(en)
|
2008-12-23 |
2010-07-01 |
The Trustees Of Columbia University In The City Of New York |
Phosphodiesterase inhibitors and uses thereof
|
JP2012513464A
(ja)
|
2008-12-23 |
2012-06-14 |
ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク |
ホスホジエステラーゼ阻害剤及びその使用
|
WO2010078536A1
(en)
|
2009-01-05 |
2010-07-08 |
Rxi Pharmaceuticals Corporation |
Inhibition of pcsk9 through rnai
|
WO2010090762A1
(en)
|
2009-02-04 |
2010-08-12 |
Rxi Pharmaceuticals Corporation |
Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
|
ES2658626T3
(es)
*
|
2009-02-12 |
2018-03-12 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con el factor neurotrófico derivado de células gliales (GDNF) por inhibición de transcrito antisentido natural a GDNF
|
CN101525388B
(zh)
*
|
2009-02-20 |
2012-02-01 |
中国人民解放军第四军医大学 |
特异性双链rna结合蛋白嵌合体及其在病毒感染性疾病中的应用
|
WO2010099341A1
(en)
|
2009-02-26 |
2010-09-02 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of mig-12 gene
|
WO2010101951A1
(en)
|
2009-03-02 |
2010-09-10 |
Alnylam Pharmaceuticals, Inc. |
Nucleic acid chemical modifications
|
WO2010105209A1
(en)
|
2009-03-12 |
2010-09-16 |
Alnylam Pharmaceuticals, Inc. |
LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 AND VEGF GENES
|
US20120035247A1
(en)
|
2009-03-19 |
2012-02-09 |
Merck Sharp & Dohme Corp. |
RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 6 (STAT6) Gene Expression Using Short Interfering Nucleic Acid (siNA)
|
US20120016011A1
(en)
|
2009-03-19 |
2012-01-19 |
Merck Sharp & Dohme Corp. |
RNA Interference Mediated Inhibition of Connective Tissue Growth Factor (CTGF) Gene Expression Using Short Interfering Nucleic Acid (siNA)
|
CA2755773A1
(en)
|
2009-03-19 |
2010-09-23 |
Merck Sharp & Dohme Corp. |
Rna interference mediated inhibition of btb and cnc homology 1, basic leucine zipper transcription factor 1 (bach 1) gene expression using short interfering nucleic acid (sina)
|
JP2012520685A
(ja)
|
2009-03-19 |
2012-09-10 |
メルク・シャープ・エンド・ドーム・コーポレイション |
低分子干渉核酸(siNA)を用いたGATA結合タンパク質3(GATA3)遺伝子発現のRNA干渉媒介性阻害
|
US20120004281A1
(en)
|
2009-03-27 |
2012-01-05 |
Merck Sharp & Dohme Corp |
RNA Interference Mediated Inhibition of the Nerve Growth Factor Beta Chain (NGFB) Gene Expression Using Short Interfering Nucleic Acid (siNA)
|
EP2411516A1
(en)
|
2009-03-27 |
2012-02-01 |
Merck Sharp&Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US20120022142A1
(en)
|
2009-03-27 |
2012-01-26 |
Merck Sharp & Dohme Corp. |
RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 1 (STAT1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
|
US20120022143A1
(en)
|
2009-03-27 |
2012-01-26 |
Merck Sharp & Dohme Corp |
RNA Interference Mediated Inhibition of the Thymic Stromal Lymphopoietin (TSLP) Gene Expression Using Short Interfering Nucliec Acid (siNA)
|
WO2010111497A2
(en)
|
2009-03-27 |
2010-09-30 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF THE INTERCELLULAR ADHESION MOLECULE 1 (ICAM-1)GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US20100297127A1
(en)
|
2009-04-08 |
2010-11-25 |
Ghilardi Nico P |
Use of il-27 antagonists to treat lupus
|
US8283332B2
(en)
|
2009-04-17 |
2012-10-09 |
University Of Louisville Research Foundation, Inc. |
PFKFB4 inhibitors and methods of using the same
|
BRPI1012750B1
(pt)
|
2009-04-22 |
2019-04-16 |
Basf Plant Science Company Gmbh |
Polinucleotídeo, vetor, célula hospedeira, método para expressar um ácido nucléico de interesse, e, uso do polinucleotídeo.
|
AU2010244122B2
(en)
|
2009-05-05 |
2015-05-14 |
Beeologics Inc. |
Prevention and treatment of Nosema disease in bees
|
WO2010141511A2
(en)
|
2009-06-01 |
2010-12-09 |
Halo-Bio Rnai Therapeutics, Inc. |
Polynucleotides for multivalent rna interference, compositions and methods of use thereof
|
EP2258858A1
(en)
|
2009-06-05 |
2010-12-08 |
Universitätsklinikum Freiburg |
Transgenic LSD1 animal model for cancer
|
LT2440183T
(lt)
|
2009-06-10 |
2018-08-10 |
Arbutus Biopharma Corporation |
Patobulinta lipido kompozicija
|
EP2266550A1
(en)
|
2009-06-15 |
2010-12-29 |
Institut Curie |
Antagonists of ß-catenin for preventing and/or treating neurodegenerative disorders
|
MX2011013421A
(es)
|
2009-06-15 |
2012-03-16 |
Alnylam Pharmaceuticals Inc |
Arnds formulado con lipido de direccionamiento del gen pcsk9.
|
WO2010147992A1
(en)
|
2009-06-15 |
2010-12-23 |
Alnylam Pharmaceuticals, Inc. |
Methods for increasing efficacy of lipid formulated sirna
|
CA2766858A1
(en)
|
2009-07-10 |
2011-01-13 |
Basf Plant Science Company Gmbh |
Expression cassettes for endosperm-specific expression in plants
|
EP2454371B1
(en)
|
2009-07-13 |
2021-01-20 |
Somagenics, Inc. |
Chemical modification of small hairpin rnas for inhibition of gene expression
|
ES2562463T3
(es)
|
2009-07-14 |
2016-03-04 |
Mayo Foundation For Medical Education And Research |
Administración no covalente, mediada por péptidos, de agentes activos a través de la barrera hematoencefálica
|
AU2010275367B2
(en)
|
2009-07-24 |
2015-09-03 |
The Regents Of The University Of California |
Methods and compositions for treating and preventing disease associated with avB5 integrin
|
EP2464336A4
(en)
|
2009-08-14 |
2013-11-20 |
Alnylam Pharmaceuticals Inc |
COMPOSITIONS FORMULATED IN LIPIDS AND METHODS OF INHIBITING THE EXPRESSION OF EBOLA VIRUS GENE
|
US20110039789A1
(en)
*
|
2009-08-14 |
2011-02-17 |
Institut Curie |
Use of Huntingtin Protein for the Diagnosis and the Treatment of Cancer
|
WO2011035065A1
(en)
|
2009-09-17 |
2011-03-24 |
Nektar Therapeutics |
Monoconjugated chitosans as delivery agents for small interfering nucleic acids
|
US20150025122A1
(en)
|
2009-10-12 |
2015-01-22 |
Larry J. Smith |
Methods and Compositions for Modulating Gene Expression Using Oligonucleotide Based Drugs Administered in vivo or in vitro
|
US8962584B2
(en)
|
2009-10-14 |
2015-02-24 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. |
Compositions for controlling Varroa mites in bees
|
WO2011063409A1
(en)
|
2009-11-23 |
2011-05-26 |
Aquabounty Technologies, Inc. |
Maternally induced sterility in animals
|
KR20120102630A
(ko)
|
2009-11-26 |
2012-09-18 |
쿠아크 파마수티칼스 인코퍼레이티드 |
말단 치환체를 포함하는 에스아이 알엔에이 화합물
|
BR112012013156A2
(pt)
|
2009-12-03 |
2017-06-13 |
Basf Plant Science Co Gmbh |
cassete de expressão, vetor, célula horpedeira, tecido de planta transgênica e método para a produção de um tecido de planta transgênica
|
CA3044884A1
(en)
|
2009-12-07 |
2011-06-16 |
Arbutus Biopharma Corporation |
Compositions for nucleic acid delivery
|
EP2509628B1
(en)
|
2009-12-07 |
2017-10-25 |
The Johns Hopkins University |
Sr-bi as a predictor of human female infertility and responsiveness to treatment
|
EP2509991B1
(en)
|
2009-12-09 |
2015-11-11 |
Nitto Denko Corporation |
Modulation of hsp47 expression
|
US8778904B2
(en)
|
2009-12-09 |
2014-07-15 |
Quark Pharmaceuticals, Inc. |
Methods and compositions for treating diseases, disorders or injury of the CNS
|
EP2509590B1
(en)
|
2009-12-10 |
2019-10-30 |
The Trustees of Columbia University in the City of New York |
Histone acetyltransferase activators and uses thereof
|
US10640457B2
(en)
|
2009-12-10 |
2020-05-05 |
The Trustees Of Columbia University In The City Of New York |
Histone acetyltransferase activators and uses thereof
|
EP3000885B1
(en)
|
2009-12-18 |
2018-07-25 |
Arrowhead Pharmaceuticals, Inc. |
Organic compositions to treat hsf1-related diseases
|
ES2749426T3
(es)
|
2009-12-18 |
2020-03-20 |
Univ British Columbia |
Métodos y composiciones para administración de ácidos nucleicos
|
CN102905763B
(zh)
|
2009-12-23 |
2015-06-17 |
诺华股份有限公司 |
脂质、脂质组合物和使用它们的方法
|
WO2011084193A1
(en)
|
2010-01-07 |
2011-07-14 |
Quark Pharmaceuticals, Inc. |
Oligonucleotide compounds comprising non-nucleotide overhangs
|
WO2011094345A1
(en)
|
2010-01-26 |
2011-08-04 |
National Jewish Health |
Methods and compositions for risk prediction, diagnosis, prognosis, and treatment of pulmonary disorders
|
WO2011094580A2
(en)
|
2010-01-28 |
2011-08-04 |
Alnylam Pharmaceuticals, Inc. |
Chelated copper for use in the preparation of conjugated oligonucleotides
|
WO2011100131A2
(en)
|
2010-01-28 |
2011-08-18 |
Alnylam Pharmacuticals, Inc. |
Monomers and oligonucleotides comprising cycloaddition adduct(s)
|
MX2012009318A
(es)
|
2010-02-10 |
2012-09-07 |
Novartis Ag |
Metodos y compuestos para el crecimiento muscular.
|
US9095504B2
(en)
|
2010-03-24 |
2015-08-04 |
Rxi Pharmaceuticals Corporation |
RNA interference in ocular indications
|
AU2011232365A1
(en)
|
2010-03-24 |
2012-10-25 |
Rxi Pharmaceuticals Corporation |
RNA interference in dermal and fibrotic indications
|
RU2615143C2
(ru)
|
2010-03-24 |
2017-04-04 |
Адвирна |
Самодоставляющие PHKi соединения уменьшенного размера
|
WO2011123468A1
(en)
|
2010-03-29 |
2011-10-06 |
Alnylam Pharmaceuticals, Inc. |
Sirna therapy for transthyretin (ttr) related ocular amyloidosis
|
US8945927B2
(en)
|
2010-03-29 |
2015-02-03 |
Universite De Strasbourg |
Polymers for delivering molecules of interest
|
WO2011123621A2
(en)
|
2010-04-01 |
2011-10-06 |
Alnylam Pharmaceuticals Inc. |
2' and 5' modified monomers and oligonucleotides
|
EP2555778A4
(en)
|
2010-04-06 |
2014-05-21 |
Alnylam Pharmaceuticals Inc |
COMPOSITIONS AND METHODS FOR INHIBITING CD274 / PD-L1 GENE EXPRESSION
|
US20130260460A1
(en)
|
2010-04-22 |
2013-10-03 |
Isis Pharmaceuticals Inc |
Conformationally restricted dinucleotide monomers and oligonucleotides
|
WO2011133876A2
(en)
|
2010-04-22 |
2011-10-27 |
Alnylam Pharmaceuticals, Inc. |
Oligonucleotides comprising acyclic and abasic nucleosides and analogs
|
WO2011133931A1
(en)
|
2010-04-22 |
2011-10-27 |
Genentech, Inc. |
Use of il-27 antagonists for treating inflammatory bowel disease
|
US9725479B2
(en)
|
2010-04-22 |
2017-08-08 |
Ionis Pharmaceuticals, Inc. |
5′-end derivatives
|
DK2561077T3
(en)
|
2010-04-23 |
2016-08-01 |
Arrowhead Res Corp |
Organic compositions for the treatment of beta-ENaC-related diseases
|
KR101223660B1
(ko)
|
2010-05-20 |
2013-01-17 |
광주과학기술원 |
HIF-2α 억제제를 유효성분으로 포함하는 관절염 예방 또는 치료용 약제학적 조성물
|
WO2011146938A1
(en)
|
2010-05-21 |
2011-11-24 |
NanoOncology, Inc. |
Reagents and methods for treating cancer
|
KR20130108983A
(ko)
|
2010-05-26 |
2013-10-07 |
셀렉타 바이오사이언시즈, 인크. |
커플링되지 않은 애주번트를 갖는 나노담체 조성물
|
WO2011151321A1
(en)
|
2010-05-31 |
2011-12-08 |
Institut Curie |
Asf1b as a prognosis marker and therapeutic target in human cancer
|
JP6081910B2
(ja)
|
2010-06-02 |
2017-02-15 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
肝線維症治療用組成物および肝線維症の治療法
|
WO2011163121A1
(en)
|
2010-06-21 |
2011-12-29 |
Alnylam Pharmaceuticals, Inc. |
Multifunctional copolymers for nucleic acid delivery
|
WO2011163466A1
(en)
|
2010-06-23 |
2011-12-29 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Regulation of skin pigmentation by neuregulin-1 (nrg-1)
|
US20130202652A1
(en)
|
2010-07-30 |
2013-08-08 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for delivery of active agents
|
WO2012016184A2
(en)
|
2010-07-30 |
2012-02-02 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for delivery of active agents
|
JP6043285B2
(ja)
|
2010-08-02 |
2016-12-14 |
サーナ・セラピューティクス・インコーポレイテッドSirna Therapeutics,Inc. |
低分子干渉核酸(siNA)を用いたカテニン(カドヘリン結合型タンパク質)β1(CTNNB1)遺伝子発現のRNA干渉媒介性阻害
|
CN108676800B
(zh)
|
2010-08-17 |
2022-11-11 |
瑟纳治疗公司 |
使用短干扰核酸(siNA)的乙型肝炎病毒(HBV)基因表达的RNA干扰介导的抑制
|
EP3372684B1
(en)
|
2010-08-24 |
2020-10-07 |
Sirna Therapeutics, Inc. |
Single-stranded rnai agents containing an internal, non-nucleic acid spacer
|
EP2609106A4
(en)
|
2010-08-26 |
2014-03-19 |
Merck Sharp & Dohme |
RNA INTERFERENCE-MEDIATED INHIBITION OF EXPRESSION OF PHD2 GENE (PROLYL HYDROXYLASE DOMAIN 2) USING SMALL INTERFERING NUCLEIC ACID (PANI)
|
EP2433644A1
(en)
|
2010-09-22 |
2012-03-28 |
IMBA-Institut für Molekulare Biotechnologie GmbH |
Breast cancer therapeutics
|
US20140134231A1
(en)
|
2010-10-11 |
2014-05-15 |
Sanford-Burnham Medical Research Institute |
Mir-211 expression and related pathways in human melanoma
|
AR083445A1
(es)
|
2010-10-14 |
2013-02-27 |
Univ Mie |
siARN CONTRA LA FIBROSIS
|
WO2012051567A2
(en)
|
2010-10-15 |
2012-04-19 |
The Trustees Of Columbia University In The City Of New York |
Obesity-related genes and their proteins and uses thereof
|
ES2663009T3
(es)
|
2010-10-29 |
2018-04-10 |
Sirna Therapeutics, Inc. |
Inhibición de la expresión génica mediada por interferencia por ARN utilizando ácidos nucleicos de interferencia cortos (ANic)
|
AU2011323508B2
(en)
|
2010-11-01 |
2017-04-27 |
Peptimed, Inc. |
Compositions of a peptide targeting system for treating cancer
|
CN103370076A
(zh)
|
2010-11-02 |
2013-10-23 |
纽约市哥伦比亚大学托管会 |
治疗毛发脱落疾病的方法
|
US9198911B2
(en)
|
2010-11-02 |
2015-12-01 |
The Trustees Of Columbia University In The City Of New York |
Methods for treating hair loss disorders
|
US9339513B2
(en)
|
2010-11-09 |
2016-05-17 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes
|
EP2455456A1
(en)
|
2010-11-22 |
2012-05-23 |
Institut Curie |
Use of kinesin inhibitors in HIV infection treatment and a method for screening them
|
US9150926B2
(en)
|
2010-12-06 |
2015-10-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Diagnosis and treatment of adrenocortical tumors using human microRNA-483
|
EP2649181B1
(en)
|
2010-12-06 |
2016-04-27 |
Quark Pharmaceuticals, Inc. |
Double stranded oligonucleotide compounds comprising positional modifications
|
US10202615B2
(en)
|
2010-12-10 |
2019-02-12 |
Vanderbilt University |
Mammalian genes involved in toxicity and infection
|
US9969677B2
(en)
|
2010-12-22 |
2018-05-15 |
The Trustees Of Columbia University In The City Of New York |
Histone acetyltransferase modulators and uses thereof
|
US20140056811A1
(en)
|
2010-12-27 |
2014-02-27 |
Compugen Ltd. |
New cell-penetrating peptides and uses thereof
|
CA2824526C
(en)
|
2011-01-11 |
2020-07-07 |
Alnylam Pharmaceuticals, Inc. |
Pegylated lipids and their use for drug delivery
|
EP2681314B1
(en)
|
2011-03-03 |
2017-11-01 |
Quark Pharmaceuticals, Inc. |
Compositions and methods for treating lung disease and injury
|
CN103562387A
(zh)
|
2011-03-03 |
2014-02-05 |
夸克医药公司 |
Toll样受体途径的寡核苷酸调剂
|
US9796979B2
(en)
|
2011-03-03 |
2017-10-24 |
Quark Pharmaceuticals Inc. |
Oligonucleotide modulators of the toll-like receptor pathway
|
WO2012119764A1
(en)
|
2011-03-08 |
2012-09-13 |
Società Bulloneria Europea S.B.E. Spa |
A high load flanged fastener to be installed by tensioning tools
|
EP2686007B1
(en)
|
2011-03-15 |
2019-04-24 |
University of Utah Research Foundation |
Methods of diagnosing and treating vascular associated maculopathy and symptoms thereof
|
KR101291668B1
(ko)
|
2011-04-21 |
2013-08-01 |
서울대학교산학협력단 |
미코박테리아―대장균용 셔틀 벡터 및 이의 용도
|
US10196637B2
(en)
|
2011-06-08 |
2019-02-05 |
Nitto Denko Corporation |
Retinoid-lipid drug carrier
|
TWI658830B
(zh)
|
2011-06-08 |
2019-05-11 |
日東電工股份有限公司 |
Hsp47表現調控強化用類視色素脂質體
|
US9068184B2
(en)
|
2011-06-21 |
2015-06-30 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibition of expression of protein C (PROC) genes
|
JP6236385B2
(ja)
|
2011-06-21 |
2017-11-22 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
アポリポタンパク質c−iii(apoc3)の発現を阻害するための組成物及び方法
|
US9228188B2
(en)
|
2011-06-21 |
2016-01-05 |
Alnylam Pharmaceuticals, Inc. |
Compositions and method for inhibiting hepcidin antimicrobial peptide (HAMP) or HAMP-related gene expression
|
EP3564393A1
(en)
|
2011-06-21 |
2019-11-06 |
Alnylam Pharmaceuticals, Inc. |
Assays and methods for determining activity of a therapeutic agent in a subject
|
EP2723390B1
(en)
|
2011-06-23 |
2017-12-27 |
Alnylam Pharmaceuticals, Inc. |
Serpina1 sirnas: compositions of matter and methods of treatment
|
US20140227293A1
(en)
|
2011-06-30 |
2014-08-14 |
Trustees Of Boston University |
Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
|
JP2014525435A
(ja)
|
2011-09-02 |
2014-09-29 |
ノバルティス アーゲー |
Hsf1関連疾患を処置するための有機組成物
|
EP2750767A4
(en)
|
2011-09-02 |
2015-10-14 |
Univ Columbia |
INHIBITORS OF CAMKII, IP3R, CALCINEURIN, P38 AND MK2 / 3 TO TREAT METABOLIC DISTURBANCES OF OBESITY
|
WO2013040251A2
(en)
|
2011-09-13 |
2013-03-21 |
Asurgen, Inc. |
Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease
|
US9352312B2
(en)
|
2011-09-23 |
2016-05-31 |
Alere Switzerland Gmbh |
System and apparatus for reactions
|
EP3456317A1
(en)
|
2011-09-27 |
2019-03-20 |
Alnylam Pharmaceuticals, Inc. |
Di-aliphatic substituted pegylated lipids
|
EP3461839A1
(en)
|
2011-10-14 |
2019-04-03 |
F. Hoffmann-La Roche AG |
Anti-htra1 antibodies and methods of use
|
WO2013059496A1
(en)
|
2011-10-18 |
2013-04-25 |
Dicerna Pharmaceuticals, Inc. |
Amine cationic lipids and uses thereof
|
BR112014010769B1
(pt)
|
2011-11-03 |
2021-08-03 |
Quark Pharmaceuticals, Inc |
Uso de um composto de rna de fita dupla para preparar um medicamento para tratar doença de ménière
|
US20140323549A1
(en)
|
2011-11-08 |
2014-10-30 |
Quark Pharmaceuticals, Inc. |
Methods and compositions for treating diseases, disorders or injury of the nervous system
|
CA2860676A1
(en)
|
2012-01-09 |
2013-07-18 |
Novartis Ag |
Organic compositions to treat beta-catenin-related diseases
|
KR101371696B1
(ko)
|
2012-02-02 |
2014-03-07 |
세종대학교산학협력단 |
벼도열병 발병인자의 스크리닝 방법
|
CN104428009A
(zh)
|
2012-02-07 |
2015-03-18 |
全球生物疗法美国有限公司 |
核酸输送的区室化方法及其组合物和应用
|
HUE040127T2
(hu)
|
2012-03-29 |
2019-02-28 |
Univ Columbia |
Eljárások hajhullási rendellenességek kezelésére
|
MX2014013367A
(es)
|
2012-05-02 |
2014-12-08 |
Novartis Ag |
Composiciones organicas para tratar enfermedades relacionadas con kras.
|
EP3358013B1
(en)
|
2012-05-02 |
2020-06-24 |
Sirna Therapeutics, Inc. |
Short interfering nucleic acid (sina) compositions
|
JP2015521041A
(ja)
|
2012-05-16 |
2015-07-27 |
サイレンス・セラピューティクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
Pkn3阻害剤投与のためのバイオマーカーとしてのvegfr1の使用
|
WO2013187556A1
(en)
|
2012-06-14 |
2013-12-19 |
Scripps Korea Antibody Institute |
Novel antibody specific for clec14a and uses thereof
|
EP2867368B1
(en)
|
2012-07-06 |
2022-01-12 |
Institut Gustave Roussy |
Simultaneous detection of cannibalism and senescence as prognostic marker for cancer
|
WO2014018375A1
(en)
|
2012-07-23 |
2014-01-30 |
Xenon Pharmaceuticals Inc. |
Cyp8b1 and uses thereof in therapeutic and diagnostic methods
|
US20150175979A1
(en)
|
2012-07-23 |
2015-06-25 |
La Jolla Institute For Allergy And Immunology |
Ptprs and proteoglycans in autoimmune disease
|
EP2700949A1
(en)
|
2012-08-24 |
2014-02-26 |
IMG Institut für medizinische Genomforschung Planungsgesellschaft M.B.H. |
Use of biliverdin reductase proteins as cancer marker
|
EP3677310A1
(en)
|
2012-10-08 |
2020-07-08 |
St. Jude Children's Research Hospital |
Therapies based on control of regulatory t cell stability and function via a neuropilin-1:semaphorin axis
|
WO2014068072A1
(en)
|
2012-10-31 |
2014-05-08 |
Institut Gustave-Roussy |
Identification, assessment and therapy of essential thrombocythemia with resistance to jak2 inhibitors
|
US9868949B2
(en)
|
2013-02-28 |
2018-01-16 |
Arrowhead Pharmaceuticals, Inc. |
Organic compositions to treat EPAS1-related diseases
|
WO2014135655A1
(en)
|
2013-03-06 |
2014-09-12 |
Institut Curie |
Compositions and methods for treating muscle-invasive bladder cancer
|
JP6352950B2
(ja)
|
2013-03-08 |
2018-07-04 |
ノバルティス アーゲー |
活性薬物の送達のための脂質と脂質組成物
|
BR112015023108A8
(pt)
|
2013-03-13 |
2018-01-23 |
Geneweave Biosciences Inc |
sistema de acondicionamento de célula bacteriana, método para acondicionamento de uma molécula de ácido nucléico repórter, composição, método para detectar uma presença ou uma ausência de uma célula bacteriana em uma amostra, vetor, método para detectar um transcrito alvo em uma célula, método para detectar a presença de uma célula bacteriana em uma amostra e kit.
|
CA2907152A1
(en)
|
2013-03-15 |
2014-09-25 |
The Trustees Of Columbia University In The City Of New York |
Fusion proteins and methods thereof
|
US9920377B2
(en)
|
2013-03-15 |
2018-03-20 |
Sutter West Bay Hospitals |
FALZ for use as a target for therapies to treat cancer
|
US9937231B2
(en)
|
2013-03-27 |
2018-04-10 |
The General Hospital Corporation |
Methods and agents for treating Alzheimer's disease
|
AU2014284396A1
(en)
|
2013-07-03 |
2016-02-04 |
City Of Hope |
Anticancer combinations
|
CN105518136A
(zh)
|
2013-07-10 |
2016-04-20 |
巴斯夫欧洲公司 |
用于通过抑制CYP51基因表达来控制致植物病真菌和卵菌的RNAi
|
EP3030663B1
(en)
|
2013-07-19 |
2019-09-04 |
Monsanto Technology LLC |
Compositions and methods for controlling leptinotarsa
|
EP3027223A1
(en)
|
2013-07-31 |
2016-06-08 |
QBI Enterprises Ltd. |
Methods of use of sphingolipid polyalkylamine oligonucleotide compounds
|
EP3027222A1
(en)
|
2013-07-31 |
2016-06-08 |
QBI Enterprises Ltd. |
Sphingolipid-polyalkylamine-oligonucleotide compounds
|
EP3030171B1
(en)
|
2013-08-08 |
2017-11-01 |
Global Bio Therapeutics, Inc. |
Injection device for minimally invasive procedures
|
MX2016001667A
(es)
|
2013-08-08 |
2016-11-07 |
Global Bio Therapeutics Inc |
Dispositivo de sujecion para procedimientos minimamente invasivos y usos del mismo.
|
WO2015051044A2
(en)
|
2013-10-04 |
2015-04-09 |
Novartis Ag |
Novel formats for organic compounds for use in rna interference
|
US10227588B2
(en)
|
2013-10-04 |
2019-03-12 |
Novartis Ag |
3′end caps for RNAi agents for use in RNA interference
|
EP3052627B1
(en)
|
2013-10-04 |
2018-08-22 |
Novartis AG |
Novel formats for organic compounds for use in rna interference
|
JP6546161B2
(ja)
|
2013-10-04 |
2019-07-17 |
ノバルティス アーゲー |
B型肝炎ウイルスを治療するための有機化合物
|
WO2015051135A2
(en)
|
2013-10-04 |
2015-04-09 |
Novartis Ag |
Organic compositions to treat hepcidin-related diseases
|
US10584387B2
(en)
|
2013-10-09 |
2020-03-10 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Detection of hepatitis delta virus (HDV) for the diagnosis and treatment of Sjögren's syndrome and lymphoma
|
JP2016537965A
(ja)
|
2013-10-11 |
2016-12-08 |
ジェネンテック, インコーポレイテッド |
Nsp4阻害剤及び使用方法
|
EP3068407A1
(en)
|
2013-11-11 |
2016-09-21 |
Sirna Therapeutics, Inc. |
Systemic delivery of myostatin short interfering nucleic acids (sina) conjugated to a lipophilic moiety
|
WO2015084897A2
(en)
|
2013-12-02 |
2015-06-11 |
Mirimmune, Llc |
Immunotherapy of cancer
|
PT3083556T
(pt)
|
2013-12-19 |
2020-03-05 |
Novartis Ag |
Lípidos e composições lipídicas para a entrega de agentes ativos
|
US10426737B2
(en)
|
2013-12-19 |
2019-10-01 |
Novartis Ag |
Lipids and lipid compositions for the delivery of active agents
|
US9682123B2
(en)
|
2013-12-20 |
2017-06-20 |
The Trustees Of Columbia University In The City Of New York |
Methods of treating metabolic disease
|
US9274117B2
(en)
|
2013-12-21 |
2016-03-01 |
Catholic University Industry Academic |
Use of SIRT7 as novel cancer therapy target and method for treating cancer using the same
|
JP6372930B2
(ja)
|
2013-12-27 |
2018-08-15 |
国立大学法人高知大学 |
悪性腫瘍の治療薬
|
ES2796090T3
(es)
|
2014-02-10 |
2020-11-25 |
Inst Curie |
Uso de moduladores MCOLN-1 para regular la migración celular
|
JP6681837B2
(ja)
|
2014-03-11 |
2020-04-15 |
セレクティスCellectis |
同種移植に適合するt細胞を作製するための方法
|
US9856475B2
(en)
|
2014-03-25 |
2018-01-02 |
Arcturus Therapeutics, Inc. |
Formulations for treating amyloidosis
|
WO2015148582A1
(en)
|
2014-03-25 |
2015-10-01 |
Arcturus Therapeutics, Inc. |
Transthyretin allele selective una oligomers for gene silencing
|
WO2015148580A2
(en)
|
2014-03-25 |
2015-10-01 |
Arcturus Therapeutics, Inc. |
Una oligomers having reduced off-target effects in gene silencing
|
KR20160138494A
(ko)
|
2014-03-31 |
2016-12-05 |
데비오팜 인터네셔날 에스 에이 |
Fgfr 융합물
|
US11091770B2
(en)
|
2014-04-01 |
2021-08-17 |
Monsanto Technology Llc |
Compositions and methods for controlling insect pests
|
WO2015168108A2
(en)
|
2014-04-28 |
2015-11-05 |
Rxi Pharmaceuticals Corporation |
Methods for treating cancer using nucleic targeting mdm2 or mycn
|
KR101633876B1
(ko)
|
2014-05-08 |
2016-06-28 |
고려대학교 산학협력단 |
정서장애 및 중독질환 치료를 위한 REV-ERBα 유전자의 용도
|
KR101633881B1
(ko)
|
2014-05-08 |
2016-06-28 |
고려대학교 산학협력단 |
도파민 의존성 신경장애 치료를 위한 REV-ERBα 유전자의 용도
|
CN106794141B
(zh)
|
2014-07-16 |
2021-05-28 |
诺华股份有限公司 |
将核酸包封在脂质纳米粒主体中的方法
|
WO2016011123A1
(en)
|
2014-07-16 |
2016-01-21 |
Arrowhead Research Corporation |
Organic compositions to treat apoc3-related diseases
|
US10378012B2
(en)
|
2014-07-29 |
2019-08-13 |
Monsanto Technology Llc |
Compositions and methods for controlling insect pests
|
CN107427552B
(zh)
|
2014-08-22 |
2022-12-20 |
广州英恩迈生物医药科技有限公司 |
防治与ifp35蛋白家族的异常水平和/或活性相关的疾病或不适的方法和组合物
|
WO2016037071A2
(en)
|
2014-09-05 |
2016-03-10 |
Rxi Pharmaceuticals Corporation |
Methods for treating aging and skin disorders using nucleic acids targeting tyr or mmp1
|
WO2016037053A1
(en)
|
2014-09-05 |
2016-03-10 |
Novartis Ag |
Lipids and lipid compositions for the delivery of active agents
|
WO2016044271A2
(en)
|
2014-09-15 |
2016-03-24 |
Children's Medical Center Corporation |
Methods and compositions to increase somatic cell nuclear transfer (scnt) efficiency by removing histone h3-lysine trimethylation
|
MX2017003892A
(es)
|
2014-09-25 |
2018-01-30 |
Cold Spring Harbor Laboratory |
Tratamiento del sindrome de rett.
|
US20170304459A1
(en)
|
2014-10-10 |
2017-10-26 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for inhalation delivery of conjugated oligonucleotide
|
EP3218497A1
(en)
|
2014-11-12 |
2017-09-20 |
NMC Inc. |
Transgenic plants with engineered redox sensitive modulation of photosynthetic antenna complex pigments and methods for making the same
|
EP3925979A3
(en)
|
2014-12-23 |
2022-03-23 |
The Trustees of Columbia University in the City of New York |
Fgfr-tacc fusion proteins and methods thereof
|
US10264976B2
(en)
|
2014-12-26 |
2019-04-23 |
The University Of Akron |
Biocompatible flavonoid compounds for organelle and cell imaging
|
EP3256589B1
(en)
|
2015-01-22 |
2021-12-22 |
Monsanto Technology LLC |
Compositions and methods for controlling leptinotarsa
|
CA2978449A1
(en)
|
2015-03-02 |
2016-09-09 |
180 Therapeutics Lp |
Method of treating a localized fibrotic disorder using an il-33 antagonist
|
WO2016145005A1
(en)
|
2015-03-09 |
2016-09-15 |
University Of Kentucky Research Foundation |
Rna nanoparticles for brain tumor treatment
|
US11085044B2
(en)
|
2015-03-09 |
2021-08-10 |
University Of Kentucky Research Foundation |
miRNA for treatment of breast cancer
|
WO2016145003A1
(en)
|
2015-03-09 |
2016-09-15 |
University Of Kentucky Research Foundation |
Rna nanoparticle for treatment of gastric cancer
|
KR101797569B1
(ko)
|
2015-03-18 |
2017-11-22 |
한국교통대학교산학협력단 |
금속 나노입자 기반 간 표적성 핵산 전달체 및 이의 제조방법
|
WO2016161299A1
(en)
|
2015-04-01 |
2016-10-06 |
Arcturus Therapeutics, Inc. |
Therapeutic una oligomers and uses thereof
|
US11279768B1
(en)
|
2015-04-03 |
2022-03-22 |
Precision Biologics, Inc. |
Anti-cancer antibodies, combination therapies, and uses thereof
|
CN107614685B
(zh)
|
2015-04-17 |
2021-10-19 |
肯塔基大学研究基金会 |
Rna纳米颗粒及其使用方法
|
EP3289104B1
(en)
|
2015-04-29 |
2020-11-04 |
New York University |
Method for treating high-grade gliomas
|
EP3307771A2
(en)
|
2015-06-12 |
2018-04-18 |
Alector LLC |
Anti-cd33 antibodies and methods of use thereof
|
US11174313B2
(en)
|
2015-06-12 |
2021-11-16 |
Alector Llc |
Anti-CD33 antibodies and methods of use thereof
|
US10669528B2
(en)
|
2015-06-25 |
2020-06-02 |
Children's Medical Center Corporation |
Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
|
US10808247B2
(en)
|
2015-07-06 |
2020-10-20 |
Phio Pharmaceuticals Corp. |
Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
|
WO2017007813A1
(en)
|
2015-07-06 |
2017-01-12 |
Rxi Pharmaceuticals Corporation |
Nucleic acid molecules targeting superoxide dismutase 1 (sod1)
|
WO2017013270A1
(en)
|
2015-07-23 |
2017-01-26 |
Universite De Strasbourg |
Use of leptin signaling inhibitor for protecting kidneys from patients having ciliopathy
|
WO2017015671A1
(en)
|
2015-07-23 |
2017-01-26 |
Arcturus Therapeutics, Inc. |
Compositions for treating amyloidosis
|
US10072065B2
(en)
|
2015-08-24 |
2018-09-11 |
Mayo Foundation For Medical Education And Research |
Peptide-mediated delivery of immunoglobulins across the blood-brain barrier
|
AU2016312530A1
(en)
|
2015-08-24 |
2018-03-01 |
Halo-Bio Rnai Therapeutics, Inc. |
Polynucleotide nanoparticles for the modulation of gene expression and uses thereof
|
CA2996059A1
(en)
|
2015-08-28 |
2017-03-09 |
Alector Llc |
Anti-siglec-7 antibodies and methods of use thereof
|
SG10202007937SA
(en)
|
2015-09-02 |
2020-09-29 |
Alnylam Pharmaceuticals Inc |
PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
EP3347486A4
(en)
|
2015-09-09 |
2019-06-19 |
The Trustees of Columbia University in the City of New York |
REDUCTION OF ER-MAM-LOCALIZED APP-C99 AND METHOD FOR THE TREATMENT OF ALZHEIMER DISEASE
|
US11285142B2
(en)
|
2015-09-29 |
2022-03-29 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Compositions and methods for identifying and treating dystonia disorders
|
US10358497B2
(en)
|
2015-09-29 |
2019-07-23 |
Amgen Inc. |
Methods of treating cardiovascular disease with an ASGR inhibitor
|
WO2017070151A1
(en)
|
2015-10-19 |
2017-04-27 |
Rxi Pharmaceuticals Corporation |
Reduced size self-delivering nucleic acid compounds targeting long non-coding rna
|
EP3368575A2
(en)
|
2015-10-29 |
2018-09-05 |
Alector LLC |
Anti-siglec-9 antibodies and methods of use thereof
|
CA3001362C
(en)
|
2015-10-30 |
2020-10-13 |
Genentech, Inc. |
Anti-htra1 antibodies and methods of use thereof
|
US10358647B2
(en)
|
2015-12-13 |
2019-07-23 |
Nitto Denko Corporation |
siRNA structures for high activity and reduced off target
|
WO2017152073A1
(en)
|
2016-03-04 |
2017-09-08 |
University Of Louisville Research Foundation, Inc. |
Methods and compositions for ex vivo expansion of very small embryonic-like stem cells (vsels)
|
US20190119642A1
(en)
|
2016-03-15 |
2019-04-25 |
Children's Medical Center Corporation |
Methods and compositions relating to hematopoietic stem cell expansion
|
WO2017173327A1
(en)
|
2016-03-31 |
2017-10-05 |
The Schepens Eye Research Institute, Inc. |
Endomucin inhibitor as an anti-angiogenic agent
|
MA45469A
(fr)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
Acides nucléiques de bêta-caténine et leurs utilisations
|
MA45349A
(fr)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
Acides nucléiques egfr et leurs utilisations
|
MA45328A
(fr)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
Compositions acide nucléique-polypeptide et utilisations de celles-ci
|
MA45470A
(fr)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
Acides nucléiques kras et leurs utilisations
|
CN116333057A
(zh)
|
2016-05-13 |
2023-06-27 |
4D分子治疗有限公司 |
腺相关病毒变体衣壳和其使用方法
|
US20190367930A1
(en)
|
2016-07-29 |
2019-12-05 |
Danmarks Tekniske Universitet |
Methods for decoupling cell growth from production of biochemicals and recombinant polypeptides
|
EP3516062A1
(en)
|
2016-09-21 |
2019-07-31 |
Alnylam Pharmaceuticals, Inc. |
Myostatin irna compositions and methods of use thereof
|
EP3548005A4
(en)
|
2016-11-29 |
2020-06-17 |
Puretech Health LLC |
EXOSOMES FOR THE ADMINISTRATION OF THERAPEUTIC AGENTS
|
US11147249B2
(en)
|
2016-12-08 |
2021-10-19 |
Alector Llc |
Siglec transgenic mice and methods of use thereof
|
EP3555138A1
(en)
|
2016-12-16 |
2019-10-23 |
Université de Bordeaux |
Mmp9 inhibitors and uses thereof in the prevention or treatment of a depigmenting disorder
|
US11359014B2
(en)
|
2017-05-16 |
2022-06-14 |
Alector Llc |
Anti-siglec-5 antibodies and methods of use thereof
|
CA3066756A1
(en)
|
2017-06-15 |
2018-12-20 |
Cancer Advances Inc. |
Compositions and methods for inducing humoral and cellular immunities against tumors and cancer
|
EP3638773A1
(en)
|
2017-06-16 |
2020-04-22 |
IMBA-Institut für Molekulare Biotechnologie GmbH |
Blood vessel organoid, methods of producing and using said organoids
|
CN117700548A
(zh)
|
2017-08-03 |
2024-03-15 |
艾利妥 |
抗cd33抗体及其使用方法
|
CN117866959A
(zh)
|
2017-09-07 |
2024-04-12 |
北京泰德制药股份有限公司 |
靶向ckip-1的双链rna分子及其用途
|
TN2020000039A1
(en)
|
2017-09-11 |
2021-10-04 |
Arrowhead Pharmaceuticals Inc |
Rnai agents and compositions for inhibiting expression of apolipoprotein c-iii (apoc3)
|
KR20220070075A
(ko)
|
2017-09-20 |
2022-05-27 |
4디 몰레큘러 테라퓨틱스 아이엔씨. |
아데노-관련 바이러스 변이체 캡시드 및 그 용도
|
CN111770999A
(zh)
|
2017-11-27 |
2020-10-13 |
4D分子治疗有限公司 |
腺相关病毒变体衣壳和用于抑制血管生成的应用
|
KR102443358B1
(ko)
|
2017-12-06 |
2022-09-14 |
어비디티 바이오사이언시스 인크. |
근위축증 및 근긴장성 이영양증을 치료하는 조성물 및 방법
|
US11470827B2
(en)
|
2017-12-12 |
2022-10-18 |
Alector Llc |
Transgenic mice expressing human TREM proteins and methods of use thereof
|
JP7348185B2
(ja)
|
2017-12-21 |
2023-09-20 |
アルニラム ファーマスーティカルズ インコーポレイテッド |
キラル富化二本鎖rna剤
|
US20210162007A1
(en)
|
2018-04-09 |
2021-06-03 |
President And Fellows Of Harvard College |
Modulating nuclear receptors and methods of using same
|
KR20210049106A
(ko)
|
2018-07-27 |
2021-05-04 |
알렉터 엘엘씨 |
항-siglec-5 항체 및 이의 사용 방법
|
US20210393740A1
(en)
|
2018-09-19 |
2021-12-23 |
La Jolla Institute For Immunology |
Ptprs and proteoglycans in rheumatoid arthritis
|
JP2022512077A
(ja)
|
2018-11-16 |
2022-02-02 |
日東電工株式会社 |
Rna干渉送達製剤及び悪性腫瘍のための方法
|
WO2021037972A1
(en)
|
2019-08-27 |
2021-03-04 |
Sanofi |
Compositions and methods for inhibiting pcsk9
|
KR102100163B1
(ko)
|
2019-09-24 |
2020-04-13 |
테고사이언스 (주) |
켈로이드 또는 비후성 반흔 예방 또는 치료용 조성물
|
US20230279394A1
(en)
|
2019-12-18 |
2023-09-07 |
Novartis Ag |
Compositions and methods for the treatment of hemoglobinopathies
|
AR120773A1
(es)
|
2019-12-18 |
2022-03-16 |
Novartis Ag |
Derivados de 3-(5-metoxi-1-oxoisoindolin-2-il)piperidin-2,6-diona como reductor de la actividad de la proteína wiz
|
AU2021205929A1
(en)
|
2020-01-08 |
2022-09-01 |
Regeneron Pharmaceuticals, Inc. |
Treatment of fibrodysplasia ossificans progressiva
|
US20210222128A1
(en)
|
2020-01-22 |
2021-07-22 |
Massachusetts Institute Of Technology |
Inducible tissue constructs and uses thereof
|
WO2021173965A1
(en)
|
2020-02-28 |
2021-09-02 |
Massachusetts Institute Of Technology |
Identification of variable influenza residues and uses thereof
|
US11555190B2
(en)
|
2020-03-19 |
2023-01-17 |
Avidity Biosciences, Inc. |
Compositions and methods of treating Facioscapulohumeral muscular dystrophy
|
WO2022147480A1
(en)
|
2020-12-30 |
2022-07-07 |
Ansun Biopharma, Inc. |
Oncolytic virus encoding sialidase and multispecific immune cell engager
|
JP2024519888A
(ja)
|
2021-05-28 |
2024-05-21 |
上海瑞宏迪医薬有限公司 |
カプシド変異を有する組換えアデノ随伴ウイルス及びその応用
|
EP4359527A2
(en)
|
2021-06-23 |
2024-05-01 |
Novartis AG |
Compositions and methods for the treatment of hemoglobinopathies
|
EP4381069A1
(en)
|
2021-08-02 |
2024-06-12 |
Universite De Montpellier |
Compositions and methods for treating cmt1a or cmt1e diseases with rnai molecules targeting pmp22
|
KR20240099259A
(ko)
|
2021-10-14 |
2024-06-28 |
아스널 바이오사이언시스, 인크. |
공동 발현된 shrna 및 논리 게이트 시스템을 갖는 면역 세포
|
WO2024059618A2
(en)
|
2022-09-13 |
2024-03-21 |
Arsenal Biosciences, Inc. |
Immune cells having co-expressed tgfbr shrnas
|
WO2024059824A2
(en)
|
2022-09-16 |
2024-03-21 |
Arsenal Biosciences, Inc. |
Immune cells with combination gene perturbations
|